10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 001-39204

AEVA TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	84-3080757
( State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
555 Ellis Street Mountain View, CA	94043
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (650) 481-7070

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.0001 par value per share	AEVA	New York Stock Exchange
Warrants to purchase one share of common stock	AEVA.WS	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 25, 2024, the registrant had 52,847,027 shares of common stock, $0.0001 par value per share, outstanding.

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	4
	Condensed Consolidated Balance Sheets	4
	Condensed Consolidated Statements of Operations and Comprehensive Loss	5
	Condensed Consolidated Statements of Stockholders' Equity	6
	Condensed Consolidated Statements of Cash Flows	8
	Notes to the Condensed Financial Statements (Unaudited)	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24
Item 4.	Controls and Procedures	24
PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	25
Item 1A.	Risk Factors	25
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25
Item 3.	Defaults Upon Senior Securities	25
Item 4.	Mine Safety Disclosures	25
Item 5.	Other Information	25
Item 6.	Exhibits	26
Signatures		27

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding future events and our future results that are subject to the safe harbors created under the Securities Act and the Exchange Act. All statements contained in this report other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “goal,” “plan,” “intend,” “expect,” “seek”, and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 under the heading “Risk Factors.” Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. We are under no duty to update any of these forward-looking statements after the date of this report or to conform these statements to actual results or revised expectations.

As used in this report, the terms “Aeva,” “we,” “us,” “our,” and “the Company” mean Aeva Technologies, Inc. and its subsidiaries unless the context indicates otherwise.

3

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

AEVA TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT PAR VALUE)

(UNAUDITED)

	March 31, 2024			December 31, 2023
Assets
Cash and cash equivalents	$	29,605		$	38,547
Marketable securities		159,723			182,481
Accounts receivable		978			628
Inventories		2,163			2,374
Other current assets		4,882			5,195
Total current assets		197,351			229,225
Operating lease right-of-use assets		6,444			7,289
Property, plant and equipment, net		12,552			12,114
Intangible assets, net		2,400			2,625
Other noncurrent assets		6,062			6,132
Total assets	$	224,809		$	257,385
Liabilities and stockholders' equity
Accounts payable	$	3,424		$	3,602
Accrued liabilities		2,639			2,648
Accrued employee costs		2,443			6,043
Lease liability, current portion		3,681			3,587
Other current liabilities		4,406			2,524
Total current liabilities		16,593			18,404
Lease liability, noncurrent portion		2,807			3,767
Warrant liability		7,209			6,772
Total liabilities		26,609			28,943
Commitments and contingencies (Note 14)
Convertible preferred stock $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding		—			—
Common stock $0.0001 par value; 422,000 shares authorized; 52,816 and 52,389 shares issued    and outstanding at March 31, 2024 and December 31, 2023, respectively		5			5
Additional paid-in capital		693,369			688,124
Accumulated other comprehensive loss		(248	)		(87	)
Accumulated deficit		(494,926	)		(459,600	)
Total stockholders' equity		198,200			228,442
Total liabilities and stockholders' equity	$	224,809		$	257,385

See accompanying notes to the unaudited condensed consolidated financial statements.

4

AEVA TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

(UNAUDITED)

	Three Months Ended March 31,
	2024			2023
Revenue	$	2,107		$	1,148
Cost of revenue		3,499			2,529
Gross loss		(1,392	)		(1,381	)
Operating expenses:
Research and development expenses		25,012			25,454
General and administrative expenses		8,411			7,833
Selling and marketing expenses		2,529			2,598
Total operating expenses		35,952			35,885
Operating loss		(37,344	)		(37,266	)
Interest income		2,458			2,064
Other income (expense), net		(439	)		28
Loss before income taxes		(35,326	)		(35,174	)
Income tax provision		—			—
Net loss	$	(35,326	)	$	(35,174	)
Unrealized gain (loss) on available-for-sale securities, net of tax		(161	)		1,212
Total comprehensive loss	$	(35,487	)	$	(33,962	)
Net loss per share, basic and diluted	$	(0.67	)	$	(0.80	)
Weighted-average shares used in computing net loss per share, basic and diluted		52,742,725			43,925,565

See accompanying notes to the unaudited condensed consolidated financial statements.

5

AEVA TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(IN THOUSANDS, EXCEPT SHARE DATA)

(UNAUDITED)

									Accumulated
	Common stock					Additional paid-in			Other Comprehensive				Accumulated			Total stockholders'
	Shares			Amount		capital			loss				deficit			equity
Balance at December 31, 2023		52,388,961		$	5	$	688,124		$	(87	)		$	(459,600	)	$	228,442
Share-based compensation		—			—		5,261			—				—			5,261
Issuance of common stock upon exercise of stock    options		28,227			—		39			—				—			39
Issuance of common stock upon release of restricted    stock units		423,869			—		—			—				—			—
Shares withheld for the withholding tax on vesting of restricted    stock units		(25,286	)		—		(55	)		—				—			(55	)
Unrealized loss on available-for-sale securities		—			—		—			(161	)			—			(161	)
Net loss					—		—			—				(35,326	)		(35,326	)
Balance as of March 31, 2024		52,815,771		$	5	$	693,369		$	(248	)	`	$	(494,926	)	$	198,200

See accompanying notes to the unaudited condensed consolidated financial statements.

6

AEVA TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(IN THOUSANDS, EXCEPT SHARE DATA)

(UNAUDITED)

									Accumulated
	Common stock					Additional paid-in			Other Comprehensive				Accumulated			Total stockholders'
	Shares			Amount		capital			loss				deficit			equity
Balance at December 31, 2022		43,749,685		$	4	$	643,774		$	(3,585	)		$	(310,267	)	$	329,926
Share-based compensation		—			—		5,963			—				—			5,963
Issuance of common stock upon exercise of stock    options		47,328			—		57			—				—			57
Issuance of common stock upon release of restricted    stock units		215,505			—		—			—				—			—
Shares withheld for the withholding tax on vesting of restricted    stock units		(2,499	)		—		(20	)		—				—			(20	)
Unrealized gain on available-for-sale securities		—			—		—			1,212				—			1,212
Net loss		—			—		—			—				(35,174	)		(35,174	)
Balance as of March 31, 2023		44,010,019		$	4	$	649,774		$	(2,373	)	`	$	(345,441	)	$	301,964

See accompanying notes to the unaudited condensed consolidated financial statements.

7

AEVA TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(UNAUDITED)

	Three Months Ended March 31,
	2024			2023
Cash flows from operating activities:
Net loss	$	(35,326	)	$	(35,174	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,345			955
Impairment of inventories		465			45
Change in fair value of warrant liabilities		437			(28	)
Stock-based compensation		5,261			5,963
Amortization of right-of-use assets		845			744
Amortization of premium and accretion of discount on available-for-sale securities, net		(1,087	)		(632	)
Changes in operating assets and liabilities:
Accounts receivable		(350	)		442
Inventories		(251	)		(100	)
Other current assets		312			790
Other noncurrent assets		70			—
Accounts payable		(89	)		(1,749	)
Accrued liabilities		(10	)		(5,207	)
Accrued employee costs		(3,600	)		(1,307	)
Lease liability		(866	)		(754	)
Other current liabilities		1,882			—
Net cash used in operating activities		(30,962	)		(36,012	)
Cash flows from investing activities:
Purchase of property, plant and equipment		(1,648	)		(1,275	)
Purchase of available-for-sale securities		(38,881	)		(54,520	)
Proceeds from maturities of available-for-sale securities		62,565			56,214
Net cash provided by investing activities		22,036			419
Cash flows from financing activities:
Payments of taxes withheld on net settled vesting of restricted stock units		(55	)		(20	)
Proceeds from exercise of stock options		39			57
Net cash provided by (used in) financing activities		(16	)		37
Net decrease in cash and cash equivalents		(8,942	)		(35,556	)
Beginning cash and cash equivalents		38,547			67,420
Ending cash and cash equivalents	$	29,605		$	31,864
Supplemental disclosures of cash flow information:
Cash paid for interest	$	—		$	—
Cash paid for income taxes	$	—		$	—
Supplemental disclosures of non-cash investing and financing activities:
Unpaid property, plant and equipment purchases	$	—		$	503

See accompanying notes to the unaudited condensed consolidated financial statements.

8

AEVA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Description of Business and Summary of Significant Accounting Policies

Description of Business

Aeva Technologies, Inc. (the “Company”), through its Frequency Modulated Continuous Wave (“FMCW”) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation and security application.

The Company’s common stock and warrants are listed on the New York Stock Exchange stock market under the symbols “AEVA” and "AEVA.WS".

Basis of Presentation and Unaudited Interim Financial Statements

The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.

The accompanying condensed consolidated financial statements are unaudited and have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period.

These condensed consolidated financial statements and other information presented in this Form 10-Q should be read in conjunction with the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC.

On March 18, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s shares of common stock, $0.0001 par value (the “Common Stock”). Pursuant to the Reverse Stock Split, every five (5) shares of issued and outstanding shares of common stock were combined into one (1) share of common stock. Accordingly, unless we indicate otherwise, all the current period and historical per share data, number of shares issued and outstanding, stock awards, and other common stock equivalents for the periods presented in this Interim Report on Form 10-Q have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. There was no change to the shares authorized or in the par value per share of common stock of $0.0001.

The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity. The Company did not issue fractional shares in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to fractional shares of common stock were instead entitled to receive a proportional cash payment. The number of shares of common stock issuable under our equity incentive plans and exercisable under the outstanding warrants were also proportionately adjusted.

Principles of Consolidation and Liquidity

The condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

The Company has funded its operations primarily through the Business Combination (the “Business Combination”) with InterPrivate Acquisition Corp. (the Company’s predecessor, which was originally incorporated in Delaware as a special purpose acquisition company (“IPV”)) on March 12, 2021, and issuances of stock. As of March 31, 2024, the Company’s existing sources of liquidity included cash and cash equivalents and marketable securities of $189.3 million. The Company has a limited history of operations and has incurred negative cash flows from operating activities and losses from operations in the past as reflected in the accumulated deficit of $494.9 million as of March 31, 2024. The Company expects to continue to incur operating losses due to the investments it intends to make in its business, including product development. Management believes that existing cash and cash equivalents and marketable securities will be sufficient to fund operating and capital expenditure requirements through at least 12 months from the date of issuance of these financial statements.

Significant Risks and Uncertainties

The Company is subject to those risks common in the technology industry and also those risks common to early stage companies including, but not limited to, the possibility of not being able to successfully develop or market its products, technological obsolescence, competition, dependence on key personnel and key external alliances, the successful protection of its proprietary technologies, compliance with government regulations, and the possibility of not being able to obtain additional financing when needed.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and trade receivables. The Company maintains the majority of its cash and cash equivalents in accounts with large financial institutions. At times, balances in these accounts may exceed federally insured limits; however, to date, the Company has not incurred any losses on its deposits of cash and cash equivalents and believes the exposure to risk of loss is not material. Risks associated with the Company’s marketable securities is mitigated by investing in investment-grade rated securities when purchased.

The Company’s accounts receivable are derived from customers located in the United States, APAC, and Europe. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers’ financial conditions and requires customer advance payments in certain circumstances.

As of March 31, 2024, three customers accounted for 44%, 15% and 12% of the accounts receivable, respectively. As of December 31, 2023, one customer accounted for 42% of accounts receivable. As of March 31, 2024, one vendor accounted for 10% of the accounts payable. As of December 31, 2023, three vendors accounted for 12%, 11% and 11% each of the accounts payable, respectively.

Recent Accounting Pronouncements

In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280):Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company does not expect ASU 2023-07 to have a material impact on the Company's financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our consolidated financial statements and related disclosures.

Note 2. Revenue

Disaggregation of Revenues

The Company disaggregates its revenue from contracts with customers by geographic region based on the primary billing address of the customer and timing of transfer of goods or services to customers (point-in-time or over time), as it believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. Total revenue for the three months ended March 31, 2024 and 2023, based on the disaggregation criteria described above were as follows (in thousands):

	Three Months Ended March 31,
	2024					2023
	Revenue		% of Revenue			Revenue		% of Revenue
Revenue by primary geographical market:
North America	$	1,674		79	%	$	730		64	%
EMEA		229		11	%		244		21	%
Asia		204		10	%		174		15	%
Total	$	2,107		100	%	$	1,148		100	%
Revenue by timing of recognition:
Recognized at a point in time	$	1,714		81	%	$	947		82	%
Recognized over time		393		19	%		201		18	%
Total	$	2,107		100	%	$	1,148		100	%

For the three months ended March 31, 2024, two customers accounted for 39% and 36% of the Company’s revenue, respectively. For the three months ended March 31, 2023, three customers accounted for 20%, 19% and 17% of the Company’s revenue, respectively.

Contract Assets and Contract Liabilities

As of March 31, 2024, and December 31, 2023, the Company had contract assets of $0.1 million and $0.1 million, respectively, recognized in other current assets. As of March 31, 2024, and December 31, 2023, the Company had contract liabilities of $3.6 million and $2.1 million, respectively, recognized in other current liabilities.

10

Note 3. Financial Instruments

The following tables summarize the Company’s financial assets and liabilities measured at fair value by level within the fair value hierarchy:

	March 31, 2024
	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalent		Marketable Securities
	(in thousands)
Assets
Cash	$	17,668	$	—	$	—		$	17,668	$	17,668	$	—
Level 1
Money market funds		264		—		—			264		264		—
Level 2
U.S. agency securities		27,635		2		(76	)		27,561		—		27,561
U.S. Treasury securities		30,255		—		(41	)		30,214		11,673		18,541
Commercial paper		42,591		6		(45	)		42,552		—		42,552
Corporate bonds		71,163		20		(114	)		71,069		—		71,069
Subtotal		171,644		28		(276	)		171,396		11,673		159,723
Total assets	$	189,576	$	28	$	(276	)	$	189,328	$	29,605	$	159,723
Liabilities
Level 3
Warrant liabilities		7,209		—		—			7,209		—		—
Total liabilities	$	7,209	$	—	$	—		$	7,209	$	—	$	—

	December 31, 2023
	Adjusted Cost		Unrealized Gain		Unrealized Losses			Fair Value		Cash and Cash Equivalent		Marketable Securities
	(in thousands)
Assets
Cash	$	21,799	$	—	$	—		$	21,799	$	21,799	$	—
Level 1
Money market funds		6,266		—		—			6,266		6,266		—
Level 2
U.S. Government securities		35,962		8		(97	)		35,873		—		35,873
U.S. Treasury securities		18,323		1		(14	)		18,310		10,482		7,828
Commercial paper		38,491		25		(16	)		38,500		—		38,500
Corporate bonds		100,274		136		(130	)		100,280		—		100,280
Subtotal		193,050		170		(257	)		192,963		10,482		182,481
Total assets	$	221,115	$	170	$	(257	)	$	221,028	$	38,547	$	182,481
Liabilities
Level 3
Warrant liabilities		6,772		—		—			6,772		—		—
Total liabilities	$	6,772	$	—	$	—		$	6,772	$	—	$	—

The fair value of the private placement and Series A warrant liabilities is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. In determining the fair value of the warrant liabilities, the Company used the Black-Scholes option-pricing model to estimate the fair value using unobservable inputs including the expected term, expected volatility, risk-free interest rate, and dividend yield.

11

The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments (in thousand):

	March 31, 2024			December 31, 2023
Fair value, beginning balance	$	6,772		$	90
Fair value at issuance of Series A warrants		—		$	6,450
Change in the fair value of Series A warrants included in other income (expense), net		450		$	300
Change in the fair value of private placement warrants included in other income (expense), net		(13	)		(68	)
Fair value, closing balance	$	7,209		$	6,772

The key inputs into the Black-Scholes option pricing model for the private warrants were as follows for the relevant periods:

	March 31, 2024			December 31, 2023
Expected term (years)		2.0			2.2
Expected volatility		90.3	%		94.1	%
Risk-free interest rate		5.03	%		4.23	%
Dividend yield		0	%		0	%
Exercise Price	$	57.50		$	57.50

The key inputs into the Black-Scholes option pricing model for the Series A warrants were as follows for the relevant periods:

	March 31, 2024			December 31, 2023
Expected term (years)		3.7			4.0
Expected volatility		92.1	%		87.2	%
Risk-free interest rate		4.29	%		3.89	%
Dividend yield		0	%		0	%
Exercise Price	$	5.00		$	5.00

Note 4. Acquisition of Intangible Assets

As of March 31, 2024, expected amortization expense relating to purchased intangible assets was as follows (in thousands):

Remainder of 2024	$	675
2025		900
2026		825
Total future amortization	$	2,400

The Company recorded amortization expense related to the acquired intangible assets of $0.2 million each for the three months ended March 31, 2024 and March 31, 2023, respectively.

Note 5. Inventories

Inventories consisted of the following (in thousands):

	March 31,		December 31,
	2024		2023
Raw materials	$	1,583	$	2,178
Work-in-progress		60		136
Finished goods		520		60
Total inventories	$	2,163	$	2,374

12

Note 6. Property, Plant and Equipment

Property, plant and equipment consisted of the following (in thousands):

	March 31,			December 31,
	2024			2023
Computer equipment	$	2,944		$	2,795
Lab equipment		7,255			7,151
Leasehold improvements		3,312			3,148
Construction in progress		700			1,434
Testing equipment		1,752			1,455
Manufacturing equipment		5,743			4,269
Furniture, fixtures and other equipment		561			458
Total property, plant and equipment	$	22,268		$	20,710
Less: accumulated depreciation		(9,716	)		(8,596	)
Total property, plant and equipment, net	$	12,552		$	12,114

Depreciation related to property, plant, and equipment was $1.1 million and $0.7 million for the three months ended March 31, 2024 and March 31, 2023, respectively.

Note 7. Other current assets

Other current assets consisted of the following (in thousands):

	March 31,		December 31,
	2024		2023
Prepaid expenses	$	2,222	$	2,228
Contract assets		111		140
Vendor deposits		975		1,104
Other current assets		1,574		1,723
Total other current assets	$	4,882	$	5,195

Note 8. Other non-current assets

Other non-current assets consist of the following (in thousands):

	March 31,		December 31,
	2024		2023
Non marketable equity investments	$	5,000	$	5,000
Security deposit		1,062	$	1,116
Other non-current assets		—		16
Total other non-current assets	$	6,062	$	6,132

In November 2023, the Company made an investment in 700,440 Preferred Stock of a private company for a cash consideration of $5.0 million, which is classified as non-marketable equity investment. The Company’s investment in the private company represents less than 1% of total capitalization. The Company neither has significant influence over the private company nor does the investment amount to a controlling financial interest in the private company. The Company elected to apply the measurement alternative, and as such, records the investment at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes in orderly transactions. During the period ended March 31, 2024, the Company did not identify any impairment or observable price changes for this non-marketable equity investment.

Note 9. Financing transaction

Private Investment

On November 8, 2023, the Company entered into Subscription Agreements (the “Subscription Agreements”) with entities affiliated with Sylebra Capital Limited (“Sylebra”) and Adage Capital Management, providing for the purchase of an aggregate of 7,360,460 shares of the Company’s common stock, $0.0001 par value per share (the “PIPE Shares”), at a price of $2.90 per PIPE Share for an aggregate purchase price of approximately $21.4 million (the “Private Placement”). The PIPE Shares are recorded as outstanding common stock.

Standby Equity Purchase Agreement

13

On November 8, 2023, the Company also entered into a Standby Equity Purchase Agreement (the “Facility Agreement”) with entities affiliated with Sylebra, pursuant to which the Company will have the right, but not the obligation to sell to Sylebra up to $125 million of its shares of Preferred Stock, subject to satisfaction of certain conditions, by November 8, 2026. Each sale the Company requests under the Facility Agreement (each, an “Advance” and collectively, the “Advances”) may be for a number of shares of preferred stock with an aggregate value of at least $25.0 million but not more than $50.0 million (except with Sylebra’s consent).

When and if issued, the preferred stock will be issued at a price per share of $10,000. Holders of the preferred stock will be entitled to a quarterly dividend at the rate of 7.0% per annum payable in cash or in kind at the option of the Company. The preferred stock will have an initial liquidation preference of $12,000 per share, plus accrued dividends. The preferred stock will have no voting rights as a class or series except in such instances as required by Delaware law or certain matters enumerated in the facility agreement related to the protection of the preferred stock.

The preferred stock will be convertible at the option of the holders into the number of shares of Common Stock equal to $10,000 divided by the then-applicable conversion price. At any time after the two year anniversary of any issuance of any series of preferred stock, the Company will have the option to convert all (but not less than all) of any series of then-outstanding preferred stock by paying a make-whole payment, in either stock or cash, equal to three years of dividends, provided that the closing price of the Common Stock exceeds 250% of the then-applicable conversion price for at least 20 out of 30 consecutive trading days prior to the date of conversion. To the extent, if any, a conversion would result in the holder thereof becoming the beneficial owner of more than 19.9% of the Company’s outstanding Common Stock, the Company will issue the Investor Pre-Funded Warrant in the form attached to the Facility Agreement. The preferred stock will be subject to customary pre-emptive rights.

The Company’s right to request Advances is conditioned upon the Company achieving a minimum of one new passenger auto-original equipment manufacturer (“OEM”) or commercial OEM program award with at least a 50,000 unit volume, the trading price of the Common Stock being below $15 at the time of the Advance request and other customary conditions. Prior to any Advance, the Company will assess its capital needs and other factors, including the impact of an Advance on the Company’s outstanding executive pledge arrangements.

The Preferred Stock issued in connection with the facility agreement ranks senior to common stock upon the Company’s liquidation, dissolution or winding up. The Preferred Stock is entitled to priority cumulative dividends which shall accrue daily from and after the original issue date of such share and shall compound on a quarterly basis on each dividend payment date. The accrued dividends shall in all cases be payable upon liquidation.

The Company shall pay dividends on each share of Preferred Stock in cash or in kind through issuance of shares of common stock with an aggregate value equal to the amount of the dividend to have been paid divided by the dividend conversion price. The board of directors of the Company may at its sole discretion elect to pay the dividends in cash in lieu of shares of common stock. The Convertible Redeemable Preferred Stock have no voting rights unless they are converted into shares of common stock.

Holders may, at their option, elect to convert some or all Preferred Stock held by such holder, at any time and from time to time prior to a change of control, into a number of shares of common stock per share of the Preferred Stock equal to (x) the quotient of the issuance price divided by the conversion price in effect at the time of conversion. At any time on or after the two-year anniversary of the issuance date, the Company shall have the right to redeem the Preferred Stock of any holder outstanding at such time at the issuance price plus three (3) years of dividend payment (“Redemption price”); provided, that (a) the closing price of a share of common stock exceeds 250% of the then-applicable conversion price per share for at least 20 out of 30 consecutive trading days prior to the redemption date and (b) a shelf registration statement that is required to be effective pursuant to the registration rights agreement on such date shall be effective on such date with respect to the applicable holder. The redemption price shall be payable in cash or in shares of common stock. Additionally, upon the occurrence of a change of control, the holders of Preferred Stock shall be entitled to receive in full a liquidating purchase in cash and in the amount per share of the Preferred Stock equal to the sum of (i) the liquidation preference plus (ii) accrued dividends with respect to such shares of Preferred Stock.

In connection with this financing, the Company also paid the entities affiliated with Sylebra, (a) a facility fee in the amount of $2.5 million, (b) an origination fee in the amount of $0.6 million, (c) an administrative fee in the amount of $0.3 million and (d) fees and expenses of the investor and its counsel, of approximately $0.4 million. The issuance costs related to the Facility Agreement were expensed as incurred as it failed to meet the equity classification guidance under ASC 815-40, and were deemed to be a derivative asset. The fair value of the derivative asset was not material as of and for the period ended March 31, 2024.

In addition, upon receipt of stockholder approval in December 2023, the Company issued to Sylebra 3,000,000 Series A Warrants to purchase shares of Common Stock at an exercise price of $5.00.

As of March 31, 2024, the Company had 3,000,000 Series A Warrants outstanding. The Series A Warrants were issued as consideration for entering into the Facility Agreement as discussed above. Each Series A Warrant entitles the holder to purchase one share of the Company’s common stock at a price of $5.00 per share. Each Series A Warrant is currently exercisable and expires in December 2027. Holders shall not have the right to exercise the Series A Warrants to the extent that after giving effect to such exercise, such person would beneficially own in excess of 19.9% of the Company’s outstanding common stock immediately after giving effect to such exercise.

The exercise price and number of shares of common stock issuable upon exercise of the Series A Warrants may be adjusted in certain circumstances including in the event of a stock dividend or split, subsequent rights offerings, pro rata purchases, merger, reorganization, recapitalization, or spin-off. However, the Series A Warrants will not be adjusted for issuances of shares of common stock at a price below their respective exercise prices. The Series A Warrants do not entitle the holders to any voting rights, dividends or other rights as a stockholder of the Company prior to being exercised for common stock.

The Company analyzed the Series A Warrants and determined that they are freestanding and do not exhibit any of the characteristics within ASC 480, and as such do not meet the characteristics of a liability under ASC 480. However, Series A Warrants do not meet all requirements for equity classification under ASC 815, and therefore are classified as a liability on the Company’s consolidated balance sheets.

14

Note 10. Capital Structure

As of March 31, 2024, the Company was authorized to issue up to 422,000,000 shares of common stock, each with a par value of $0.0001 per share.

Preferred Stock

As of March 31, 2024, the Company was authorized to issue up to 10,000,000 shares of preferred stock, each with a par value of $0.0001 per share. As of March 31, 2024 and December 31, 2023, no shares of preferred stock were issued and outstanding.

Warrants

As of March 31, 2024, the Company had 2,414,975 public and 76,800 private warrants outstanding. Each warrant entitles the registered holder to purchase one share of common stock at a price of $57.50 per share. Additionally, the Company also issued 3,000,000 Series A Warrants issued in connection with the facility agreement. Each Series A Warrants entitles the registered holder to purchase one share of common stock at an exercise price of $5.00 per share.

Note 11. Earnings (Loss) Per Share

The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except per share data):

	Three Months Ended March 31,
	2024			2023
Numerator:
Net loss attributable to common stockholders	$	(35,326	)	$	(35,174	)
Denominator:
Weighted average shares of common stock outstanding — Basic and Diluted		52,742,725			43,925,565
Net loss per share attributable to common stockholders — Basic and Diluted	$	(0.67	)	$	(0.80	)

The following table presents the potential common shares outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been anti-dilutive:

	Three Months Ended March 31,
	2024		2023
Common stock options issued and outstanding		2,386,503		2,634,606
Restricted stock units		5,484,398		4,348,913
Performance-based restricted stock units		1,911,765		—
Common stock warrants		2,491,775		2,491,775
Series A warrants		3,000,000		—
Total		15,274,441		9,475,294

Note 12. Stock-based Compensation

Stock Options

The Company maintains the 2016 Stock Incentive Plan and the 2021 Incentive Award Plan (the “Stock Plans”) under which incentive stock options, non-qualified stock options and restricted stock units (“RSU”) may be granted to employees. Under the Stock Plans, the Company has 3,677,480 shares available for issuance as of March 31, 2024.

Under the terms of the Stock Plans, incentive stock options must have an exercise price at or above the fair market value of the stock on the date of the grant, while non-qualified stock options are permitted to be granted below fair market value of the stock on the date of grant. The majority of stock options granted have service-based vesting conditions only. The service-based vesting conditions vary, typically stock options vest over four years with 25% of stock options vesting on the first anniversary of the grant and the remaining 75% vesting monthly over the remaining 36 months. Option holders have a ten-year period to exercise the options before they expire.

15

A summary of the Company’s stock option activity, for three months ended March 31, 2024, was as follows:

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2023		2,414,730		$	2.79		5.73	$	4,004
Granted		—			—		—		—
Exercised		(28,227	)		1.37		—		—
Forfeited		—			—		—		—
Outstanding as of March 31, 2024		2,386,503		$	2.81		5.49	$	4,253
Vested and exercisable as of March 31, 2024		2,317,344		$	2.46		5.42	$	4,251
Vested and expected to vest as of March 31, 2024		2,386,503		$	2.81		5.49	$	4,253

There were no options granted during the three months ended March 31, 2024. As of March 31, 2024, the Company had $0.5 million of unrecognized stock-based compensation expense related to the stock options. This cost is expected to be recognized over a weighted-average period of 1.65 years.

Restricted Stock Units (“RSUs”) and Performance-based Restricted Stock Units (“PBRSUs”)

In May 2023, the Company granted a total of 1,176,471 PBRSUs to certain executives that vest on achieving certain operational milestones as defined in the individual grant agreements subject to continued employment through 2025. Stock-based compensation expense is recognized over the expected performance achievement period of individual performance milestones when the achievement of each individual performance milestone becomes probable. If satisfaction of the performance condition is not probable, stock-based compensation cost recognition is deferred until it becomes probable. The Company reassesses the probability as to whether satisfaction of the performance condition is probable on a quarterly basis, and stock-based compensation cost is adjusted based on the portion of the requisite service provided. These PBRSUs neither carry rights to dividends nor voting rights until the shares are issued or transferred to the recipient. Awards are forfeited if an employee leaves the Company before the PBRSUs vest or the performance period lapses. The weighted-average grant date PBRSU fair value of $5.10 per share is determined based upon the market closing price of the Company’s common stock on the date of grant. As of March 31, 2024, the total unrecognized compensation expense related to the performance-based PBRSUs was $1.3 million, which is expected to be amortized over a weighted-average period of 1.8 years.

In May 2023, the Company also granted a total of 735,294 market-based PBRSUs to certain executives that vest over a multi-year period, upon continued service and when the volume-weighted average price per share (“WVAP Average”) of the Company’s common stock for the preceding 30 consecutive trading days equals or exceeds the target stock price for the indicated year. The Company recognizes stock-based compensation based upon the grant date fair value on an accelerated attribution basis over the requisite service period of the award. Provided that the requisite service is rendered, the total fair value of the market-based PBRSUs at the date of grant is recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the achievement of the specified market criteria. These PBRSUs neither carry rights to dividends nor voting rights until the shares are issued or transferred to the recipient. Awards are forfeited if an employee leaves the Company before the PBRSUs vest. The weighted-average grant date fair value of the market-based PBRSUs was $1.40 per share. The Company estimated the fair value of the market-based PBRSUs award on the grant date using the Monte Carlo simulation model with the following assumptions:

Expected term (years)	0.5 - 4.7
Expected volatility		70.9	%
Risk-free interest rate		3.29	%
Dividend yield		0	%
Share price	$	5.10

As of March 31, 2024, the total unrecognized compensation expense related to the market-based PBRSUs was $0.7 million, which is expected to be amortized over a weighted-average period of 3 years.

The following table summarizes our RSU activity for the three months ended March 31, 2024:

	Shares			Weighted Average Grant Date Fair Value per Share
Outstanding as of December 31, 2023		5,204,177		$	9.65
Granted		889,257			5.05
Released		(398,583	)		12.91
Forfeited		(210,453	)		8.83
Outstanding as of March 31, 2024		5,484,398		$	8.69

16

As of March 31, 2024, the Company had $39.6 million of unrecognized stock-based compensation expense related to the RSUs. This cost is expected to be recognized over a weighted-average period of 2.90 years. The above table excludes 1,911,765 PBRSUs granted to certain executive officers during the year ended December 31, 2023, and are outstanding as of March 31, 2024.

Compensation expense

Total stock-based compensation expense by function was as follows (in thousands):

	Three Months Ended March 31,
	2024		2023
Cost of revenue	$	102	$	330
Research and development expenses		3,989		4,410
General and administrative expenses		907		1,119
Sales and marketing expenses		263		104
Total	$	5,261	$	5,963

Note 13. Income Taxes

There has historically been no federal or state provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. For the three months ended March 31, 2024 and 2023, the Company recognized no provision for income taxes.

The federal and state net operating loss carryforwards may be subject to significant limitations under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and similar provisions under state law. The Tax Reform Act of 1986 contains provisions that limit the federal net operating loss carryforwards that may be used in any given year in the event of special occurrences, including significant ownership changes. The Company has completed an analysis as of December 31, 2022 and doesn’t expect any net operating loss carryforwards or tax credit carryforwards to expire due to a limitation.

Note 14. Commitments and Contingencies

Leases

The weighted-average remaining lease terms were 1.9 years and 2.0 years as of March 31, 2024 and December 31, 2023, respectively. The weighted-average discount rates were 6.32% and 6.04% as of March 31, 2024 and December 31, 2023, respectively. Operating lease cost for three months ended March 31, 2024 and 2023, was $1.0 million and $0.8 million, respectively.

The following is a maturity analysis of the annual undiscounted cash flows reconciled to the carrying value of the operating lease liabilities as of March 31, 2024 (in thousands):

	Operating Leases
Remainder of 2024	$	2,974
2025		3,157
2026		729
Total minimum lease payments		6,860
Less: imputed interest		(372	)
Total lease liability	$	6,488

Litigation

From time to time, the Company is involved in actions, claims, suits, and other proceedings in the ordinary course of business, including assertions by third parties relating to intellectual property infringement, breaches of contract or warranties, or employment-related matters. When it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated, the Company records a liability for such loss contingencies. The Company’s estimates regarding potential losses and materiality are based on the Company’s judgment and assessment of the claims utilizing currently available information. Although the Company will continue to reassess its reserves and estimates based on future developments, the Company’s objective assessment of the legal merits of such claims may not always be predictive of the outcome and actual results may vary from the Company’s current estimates.

Litigation – other matters

On March 7, 2024, a putative class action lawsuit was filed in the Court of Chancery of the State of Delaware against InterPrivate Acquisition Management LLC, InterPrivate LLC, and former directors and officers of InterPrivate Acquisition Corp (“IPV”). The lawsuit is captioned, Louis Smith v. Ahmed M. Fattouh, et al., (Del. Ch. 2024). Among other remedies, the complaint seeks damages and attorneys’ fees and costs. In connection with IPV’s March 12, 2021, merger transaction with Aeva Inc., Aeva granted certain indemnification rights to IPV’s former directors and officers. However, neither Aeva nor its current directors or officers are named as defendants in the complaint.

17

Indemnifications

In the ordinary course of business, the Company is not subject to potential obligations under guarantees that fall within the scope of FASB ASC Guarantees, (Topic 460), except for standard indemnification provisions that are contained within many of the Company’s customer agreements and give rise only to disclosure requirements prescribed by Topic 460. Indemnification provisions contained within the Company’s customer agreements are generally consistent with those prevalent in the Company’s industry. The Company has not incurred any obligations under customer indemnification provisions and does not expect to incur significant obligations in the future. Accordingly, the Company does not maintain accruals for potential customer indemnification obligations.

Note 15. Segment Information

The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision-maker (“CODM”), consisting of the Company’s chief executive officer and the Company’s chief technology officer as a group, in deciding how to allocate resources and assess the Company’s financial and operational performance. In addition, the Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. As a result, the Company has determined that the Company’s business operates in a single operating segment. Since the Company operates as one operating segment, all required financial segment information can be found in the financial statements.

Long-Lived Assets

The following table sets forth the Company’s property, plant, and equipment, net by geographic region (in thousands):

	March 31,		December 31,
	2024		2023
North America	$	8,580	$	8,675
Asia		3,657		3,154
Others		315		285
Total	$	12,552	$	12,114

18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion of Aeva’s results of operations and financial condition should be read in conjunction with the information set forth in the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q. This discussion may contain forward-looking statements based upon Aeva’s current expectations, estimates, and projections that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements due to, among other considerations, the matters discussed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”) under the heading “Risk Factors” and “Special Note Regarding Forward-Looking Statements.” Unless the context otherwise requires, all references in this section to “we,” “our,” “us” “the Company” or “Aeva” refer to the business of Aeva Technologies, Inc., a Delaware corporation, and its subsidiaries.

On March 18, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s shares of common stock, $0.0001 par value (the “Common Stock”). Pursuant to the Reverse Stock Split, every five (5) shares of issued and outstanding shares of common stock were combined into one (1) share of common stock. All share and per share amounts and related stockholders’ equity balances presented herein have been retroactively adjusted to reflect the Reverse Stock Split. There was no change to the shares authorized or in the par value per share of common stock of $0.0001.

The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity. The Company did not issue fractional shares in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to fractional shares of common stock were instead entitled to receive a proportional cash payment. The number of shares of common stock issuable under our equity incentive plans and exercisable under the outstanding warrants were also proportionately adjusted.

Overview

Our vision is to bring perception to broad applications. Through our FMCW sensing technology, we believe we are introducing the world’s first 4D LiDAR-on-chip that, along with our proprietary software applications, has the potential to enable the adoption of LIDAR across broad applications.

Founded in 2017 by former Apple engineers Soroush Salehian and Mina Rezk and led by a multidisciplinary team of engineers and operators experienced in the field of sensing and perception, Aeva’s mission is to bring the next wave of perception technology to broad applications from automated driving to industrial automation, consumer device applications, and security. Our 4D LiDAR-on-chip combines silicon photonics technology that is proven in the telecom industry with precise instant velocity measurements and long-range performance for commercialization.

As a development stage company, we work closely with our customers on the development and commercialization of their programs and the utilization of our products in such programs. Thus far, our customers have purchased prototype products and engineering services from us for use in their research and development programs. We are expanding our manufacturing capacity through third-party manufacturers to meet our customers’ anticipated demand for the production of our products.

Unlike legacy 3D LiDAR, which relies on Time-of-Flight (“ToF”) technology and measures only depth and reflectivity, Aeva’s solution leverages a proprietary FMCW technology to measure velocity in addition to depth, reflectivity and inertial motion. We believe the ability of Aeva’s solution to measure instant velocity for every pixel is a major advantage over ToF-based sensing solutions. Furthermore, Aeva’s technology is free from interference from other LiDAR and sunlight, and our core innovations within FMCW are intended to enable autonomous vehicles to see at significantly higher distances of up to 500 meters.

We believe Aeva is uniquely positioned to provide a superior solution with the potential to enable higher level of automation for vehicles. Furthermore, we believe the advantages of our 4D LiDAR-on-chip allow us to provide the first LiDAR solution that is fully integrated onto a chip with superior performance at scale, with the potential to drive new categories of perception across industrial automation, consumer devices, and security markets.

Key Factors Affecting Aeva’s Operating Results

Aeva believes that its future performance and success depends to a substantial extent on its ability to capitalize opportunities, which in turn is subject to significant risks and challenges, including those discussed in Part I, Item 1A of the 2023 Form 10-K under the heading “Risk Factors.”

Pricing, Product Cost and Margins. Our pricing and margins will depend on the volumes and the features as well as specific market applications of the solutions we provide to our customers. We have customers with technologies in various stages of development across different market segments. We anticipate that our prices will vary by market and application due to market-specific product and commercial requirements, supply and demand dynamics and product lifecycles.

Aeva’s future performance will depend on its ability to deliver on economies of scale. Our customers will require that our perception solutions be manufactured and sold at per-unit prices that are competitive. Our ability to compete in key markets will depend on the success of our efforts to efficiently and reliably produce cost-effective perception solutions that are competitively priced and affordable for our commercial-stage customers.

Additionally, the macroeconomic conditions in the industry, the growing emergence of competition in advanced assisted driving sensing and software technologies globally can negatively impact pricing, margins and market share. If Aeva does not generate the margins it expects upon

19

commercialization of its perception solutions, Aeva may be required to raise additional debt or equity capital, which may not be available or may only be available on terms that are onerous to Aeva’s stockholders.

Commercialization of LiDAR-based Applications. We expect that our results of operations, including revenue and gross margins, will fluctuate on a quarterly basis for the foreseeable future as our customers continue on research and development projects and begin to commercialize advanced driver assist, autonomous and industrial automation solutions that rely on LiDAR technology. As more customers reach the commercialization phase and as the market for LiDAR solutions matures, these fluctuations in our operating results may become less pronounced.

Sales Volume. Each product program will have an expected range of sales volumes, depending on the end market demand for our customers’ products as well as market application. This can depend on several factors, including market penetration, product capabilities, size of the end market that the product addresses and our end customers’ ability to sell their products. In addition to end market demand, sales volumes also depend on whether our customer is in the development or production phase. In certain cases, we may provide volume discounts or strategic customer pricing on sales of our solutions, which may or may not be offset by lower manufacturing costs related to higher volumes which in turn could adversely impact our gross margins. Aeva’s ability to ultimately achieve profitability is dependent upon progression of existing relationships to production and our ability to meet required volumes and required cost targets and gross margins. Delays of our current and future customers’ programs could result in Aeva being unable to achieve its revenue targets and profitability in the time frame it anticipates. Such delays could result in Aeva requiring to raise additional debt or equity capital, which may not be available or may only be available on terms that are onerous to Aeva’s stockholders.

Basis of Presentation

Our condensed consolidated financial statements include the accounts of our wholly owned subsidiaries. We have eliminated intercompany accounts and transactions.

Components of Results of Operations

Revenue

Revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services.

Aeva is engaged in design, manufacturing and sale of LiDAR sensing systems and related perception and autonomy-enabling software solutions serving customers in automotive, industrial, and other markets. Under the customer agreements, Aeva delivers a specified number of sensing systems at a fixed price under customary terms and conditions. The sensing system units sold under these agreements are typically prototypes that are used by the customer for its research, development, evaluation, pilot, or testing purposes. Aeva also enters into non-recurring engineering service arrangements with certain of its customers to customize Aeva’s perception solution to meet customer specific requirements.

Cost of revenue and gross profit

Cost of revenue principally includes direct material, direct labor and allocation of overhead associated with manufacturing operations, including inbound freight charges and depreciation expense. Cost of revenue also includes the direct cost and appropriate allocation of overhead involved in execution of non-recurring engineering services. Aeva’s gross profit (loss) equals total revenue less total cost of revenue.

Operating expenses

Research and development expenses

Aeva’s research and development efforts are focused on enhancing and developing additional functionality for its existing products and on new product development. Research and development expenses consist primarily of:

•Personnel-related expenses, including salaries, benefits, and stock-based compensation expense, for personnel in Aeva’s research and engineering functions; and

•Expenses related to materials, software licenses, supplies, and third-party services.

Aeva recognizes research and development expenses as incurred.

General and administrative expenses

General and administrative expenses consist of personnel and personnel-related expenses, including salaries, benefits, and stock-based compensation expense of Aeva’s executive, finance, information systems, human resources, and legal, as well as legal and accounting fees for professional and contract services.

Selling and marketing expenses

Selling and marketing expenses consist of personnel and personnel-related expenses, including salaries, benefits, and stock-based compensation expense of Aeva’s business development team as well as advertising and marketing expenses. These include the cost of trade shows, promotional materials, and public relations.

20

Aeva’s operating expenses will remain similar to the fiscal year 2023 or slightly increase in 2024 as we continue to execute on our goals and product roadmap.

Interest income and Interest expense

Interest income consists primarily of income earned on Aeva’s cash equivalents and investments in marketable securities. Interest income will vary based on Aeva’s cash equivalents and marketable securities balance and changes in the interest rates.

Other income and expense

Other income and expense primarily consist of changes in the fair value of private placement warrants and Series A warrants, foreign currency transaction gains and losses, and realized gains and losses on marketable securities.

Results of Operations

Comparison of the Three Months Ended March 31, 2024 and 2023

The results of operations presented below should be reviewed in conjunction with the financial statements and notes included elsewhere in this quarterly statement. The following table sets forth Aeva’s results of operations data for the periods presented:

	Three Months Ended March 31,
	2024			2023			Change $			Change %
	(in thousands, except percentages)
Revenue	$	2,107		$	1,148			959			84	%
Cost of revenue		3,499			2,529			970			38	%
Gross loss		(1,392	)		(1,381	)		(11	)		1	%
Operating expenses:
Research and development expenses		25,012			25,454			(442	)		(2	)%
General and administrative expenses		8,411			7,833			578			7	%
Selling and marketing expenses		2,529			2,598			(69	)		(3	)%
Total operating expenses		35,952			35,885			67			0	%
Loss from operations		(37,344	)		(37,266	)		(78	)		0	%
Interest income		2,458			2,064			394			19	%
Other income (expense), net		(439	)		28			(467	)		(1669	)%
Net loss before taxes		(35,326	)		(35,174	)		(152	)		0	%
Income tax provision		—			—			-
Net loss	$	(35,326	)	$	(35,174	)		(152	)		0	%

Revenue

Revenue increased by approximately $1.0 million or 84% during the three months ended March 31, 2024 as compared to the three months ended March 31, 2023. The increase was primarily due to a $0.8 million increase in the sale of prototype units sold during the three months ended March 31, 2024 as compared to the three months ended March 31 2023. The revenue related to non-recurring engineering services, which is dependent upon the timing of the work performed for our customers also increased by $0.2 million for the three months ended March 31, 2024. This increase was partially offset by a decrease in average selling price per unit for the prototype units.

Cost of revenue

Cost of revenue increased by approximately $1.0 million or 38%, during the three months ended March 31, 2024, from the three months ended March 31, 2023. The increase was primarily due to an increase in number of units sold during the three months ended March 31, 2024 as compared to the three months ended March 31 2023 and also due to increase in cost of revenue related to non-recurring engineering services.

Operating expenses

Research and development expenses

Research and development expenses decreased by approximately $0.4 million, or 2%, to $25.0 million for the three months ended March 31, 2024, from $25.4 million for the three months ended March 31, 2023. Research and development expenses decreased primarily due to a decrease of $2.1 million in research material expenses related to product development, this was partially offset by a $0.8 million increase in payroll related expenses, a $0.5 million increase in service costs, and a $0.4 million increase in depreciation and amortization.

21

General and administrative expenses

General and administrative expenses increased by approximately $0.6 million, or 7%, to $8.4 million for the three months ended March 31, 2024, from $7.8 million for the three months ended March 31, 2023. General and administrative expenses increased primarily due to increases in payroll related expense of $0.7 million, and professional fees expenses of $0.3 million. This was partially offset by a decrease in insurance expenses of $0.4 million.

Selling and marketing expenses

Selling and marketing expenses decreased by approximately $0.1 million, or 3%, to $2.5 million for the three months ended March 31, 2024, from $2.6 million for the three months ended March 31, 2023. The decrease was primarily due to a decrease in payroll related expenses of $0.3 million, this was partially offset by an increase in marketing related expenses of $0.2 million.

Interest income

Interest income increased by $0.4 million, or 19%, during the three months ended March 31, 2024, as compared to the three months ended March 31, 2023. The increase was due to change in our investment portfolio, as the Company invested in higher interest bearing securities on the maturity of certain securities during three months ended March 31, 2024 as compared to the three months ended March 31, 2023. This was partially offset by change in the overall balance of marketable securities.

Other income (expense), net

Other income decreased by $0.5 million for the three months ended March 31, 2024 primarily due to the change in the fair value of Series A warrant liability.

Liquidity and Capital Resources

Sources of Liquidity

Aeva’s capital requirements will depend on many factors, including sales volume, the timing and extent of spending to support research and development efforts, investments in information technology systems, the expansion of sales and marketing activities, and market adoption of new and enhanced products and features. As of March 31, 2024, Aeva had cash and cash equivalents and marketable securities totaling $189.3 million.

On November 8, 2023, the Company entered into Subscription Agreements providing for the purchase of common stock resulting in net proceeds of $20.6 million (“November PIPE”). Also on November 8, 2023, the Company entered into a Standby Equity Purchase Agreement (the “Facility Agreement”) with entities affiliated with Sylebra. Pursuant to the Facility Agreement, the Company will have the right, but not the obligation, to sell to Sylebra up to $125.0 million shares of its preferred stock, at the Company’s request until November 8, 2026. Each sale the Company requests under the Facility Agreement may be for a number of shares of preferred stock with an aggregate value of at least $25.0 million but not more than $50.0 million (except with Sylebra’s consent). The Company paid Sylebra a facility fee in the amount of $2.5 million, an origination fee in the amount of $0.6 million, and an administrative fee in the amount of $0.3 million and reimbursed $0.4 million to Sylebra for its fees and expenses. In addition, the Company issued to Sylebra a Series A Warrants to purchase 3,000,000 shares of Common Stock at an exercise price of $5.00.

Aeva expects current cash, cash equivalents, and marketable securities will be sufficient to fund its near term cash needs but will be required to raise additional capital or draw on the Facility Agreement (see Note 9 to our condensed consolidated financial statements) unless Aeva is able to generate sufficient revenue from the sale of its products to cover operating expense, working capital and capital expenditures.

Aeva has incurred negative cash flows from operating activities and losses from operations in the past as reflected in its accumulated deficit of $494.9 million as of March 31, 2024. Aeva expects to continue to incur operating losses due to continued investments that it intends to make in its business, including development of products. Aeva believes that existing cash and cash equivalent and marketable securities will be sufficient to fund operating and capital expenditure requirements through at least 12 months from the date of issuance of these financial statements.

Cash Flow Summary

The following table summarizes our cash flows for the periods presented:

	Three Months Ended March 31,
	2024			2023
	(in thousands)
Cash used in operating activities	$	(30,962	)	$	(36,012	)
Cash provided by investing activities		22,036			419
Cash provided by (used in) financing activities		(16	)		37
Net decrease in cash and cash equivalents	$	(8,942	)	$	(35,556	)

Operating Activities

For the three months ended March 31, 2024, net cash used in operating activities was $31.0 million, attributable to a net loss of $35.3 million and a net change in net operating assets and liabilities of $2.9 million, partially offset by non-cash charges of $7.3 million. Non-cash charges

22

primarily consisted of $5.3 million in stock-based compensation, $1.3 million in depreciation and amortization expense, $0.9 million in amortization of right of use assets, $0.5 million in impairment of inventory and $0.4 million in change in the fair value of warrant liabilities partially offset by $1.1 million in amortization of premium and accretion of discount on available for sale securities. The increase in net operating assets and liabilities of $2.9 million was primarily due to a $3.6 million decrease in accrued employee costs, a $0.9 million decrease on lease liability, a $0.4 million increase in accounts receivable and a $0.3 million increase in inventory, this was offset by a $1.9 million increase in other current liabilities and a $0.4 million decrease in other current and non-current assets.

Investing Activities

For the three months ended March 31, 2024, net cash provided by investing activities was $22.0 million, attributable to maturity of available-for-sale investments of $62.5 million, partially offset by purchase of investments of $38.9 million and purchase of property, plant and equipment of $1.6 million.

Financing Activities

For the three months ended March 31, 2024, net cash used by financing activities was attributable to a $0.04 million proceeds from stock option exercises, offset by $0.06 million of payments of taxes withheld on net settled vesting of restricted stock units.

Off-Balance Sheet Arrangements

As of March 31, 2024, Aeva has not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Critical Accounting Policies and Estimates

Aeva prepares its financial statements in accordance with U.S. GAAP. The preparation of these financial statements requires the Company to make estimates, assumptions and judgments that can significantly impact the amounts Aeva reports as assets, liabilities, revenue, costs and expenses and the related disclosures. Aeva bases its estimates on historical experience and other assumptions that it believes are reasonable under the circumstances. Aeva’s actual results could differ significantly from these estimates under different assumptions and conditions. Aeva believes that the accounting policies discussed below are critical to understanding its historical and future performance as these policies involve a greater degree of judgment and complexity.

For the three months ended March 31, 2024 there were no significant changes to our critical accounting policies and estimates. For a more detailed discussion of our critical accounting policies and estimates, please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and Note 1 of the notes to condensed consolidated financial statements included in this Form 10-Q.

Recent Accounting Pronouncements

Note 1 to Aeva’s financial statements included elsewhere in this Quarterly Report on Form 10-Q for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of the date of this Quarterly Report on Form 10-Q.

23

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Aeva is exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates. There has been no material change in our exposure to market risks from that discussed in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of the 2023 Form 10-K.

Item 4. Controls and Procedures.

Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of March 31, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in internal control over financial reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent limitation on the effectiveness of internal control

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

24

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, the Company may be involved in actions, claims, suits and other proceedings in the ordinary course of business, including assertions by third parties relating to intellectual property infringement, breaches of contract or warranties or employment-related matters. Information regarding legal proceedings is provided in this Quarterly Report in “Notes to Condensed Consolidated Financial Statements, Note 14 Commitments and Contingencies.”

Item 1A. Risk Factors.

The Company’s business, reputation, results of operations and financial condition, as well as the price of the Company’s stock, can be affected by a number of factors, whether currently known or unknown, including those described in Part I, Item 1A of the 2023 Form 10-K under the heading “Risk Factors.” When any one or more of these risks materialize from time to time, the Company’s business, reputation, results of operations and financial condition, as well as the price of the Company’s stock, can be materially and adversely affected. There have been no material changes to the Company’s risk factors since the 2023 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceed.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

10b5-1 Trading Plans

During the fiscal quarter ended March 31, 2024, no Section 16 director or officer adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act).

There were no “non-Rule 10b5-1 trading arrangements” (as defined in Item 408 of Regulation S-K of the Exchange Act) adopted, modified or terminated during the fiscal quarter ended March 31, 2024 by our directors and Section 16 officers.

25

Item 6. Exhibits.

Exhibit Number	Description
3.1	Second Amended and Restated Certificate of Incorporation of Aeva Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on March 18, 2021).
3.2	Amended and Restated By-laws of Aeva Technologies, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed by the Registrant on March 18, 2021).
3.3*	Aeva Technologies, Inc. Performance-Based Restricted Stock Unit Agreement (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on March 18, 2024).
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document
101.SCH	Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

26

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AEVA TECHNOLOGIES, INC.
Date: May 8, 2024	By:	/s/Soroush Salehian Dardashti
		Soroush Salehian Dardashti
		Chief Executive Officer
Date: May 8, 2024	By:	/s/ Saurabh Sinha
		Saurabh Sinha
		Chief Financial Officer

27

EX-3.3

Exhibit 3.3

AEVA TECHNOLOGIES, INC.

2021 INCENTIVE AWARD PLAN

PERFORMANCE-BASED RESTRICTED STOCK UNIT GRANT NOTICE

Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2021 Incentive Award Plan (as may be amended from time to time, the “Plan”) of Aeva Technologies, Inc. (the “Company”).

The Company has granted to the participant listed below (“Participant”) the Performance-Based Restricted Stock Units described in this Grant Notice (the “PSUs”), subject to the terms and conditions of the Plan and the Performance-Based Restricted Stock Unit Agreement attached as Exhibit A (the “Agreement”), both of which are incorporated into this Grant Notice by reference.

Participant:

Grant Date:

Number of PSUs: , consisting of: [__________________]

Performance Period:	[__________________]
Vesting Schedule:	[__________________]
Change in Control:	[__________________]
Dividend Equivalents:	[__________________]

* * *

By accepting (whether in writing, electronically or otherwise) the PSUs, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.

AEVA TECHNOLOGIES, INC.	PARTICIPANT
By:
Name:	[Participant Name]
Title:

[Signature Page to Performance-Based Restricted Stock Unit Agreement]

PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT

Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.

ARTICLE I

GENERAL

1.1Award of PSUs. The Company has granted the PSUs to Participant effective as of the grant date set forth in the Grant Notice (the “Grant Date”). Each PSU represents the right to receive one Share or, at the option of the Company, an amount of cash, in either case, as set forth in this Agreement. Participant will have no right to the distribution of any Shares or payment of any cash until the time (if ever) the PSUs have vested.

1.2Incorporation of Terms of Plan. The PSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.

1.3Unsecured Promise. The PSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company’s general assets.

ARTICLE IIVESTING; FORFEITURE AND SETTLEMENT

2.1Vesting; Forfeiture. The PSUs will vest according to the vesting schedule in the Grant Notice except that any fraction of a PSU that would otherwise be vested will be accumulated and will vest only when a whole PSU has accumulated. In the event of Participant’s Termination of Service for any reason, all unvested PSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.

2.2Settlement.

(a)PSUs will be paid in Shares or cash at the Company’s option as soon as administratively practicable after the vesting of the applicable PSU, but in no event more than sixty (60) days after the PSU’s vesting date. Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)), provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section 409A.

(b)If a PSU is paid in cash, the amount of cash paid with respect to the PSU will equal the Fair Market Value of a Share on the day immediately preceding the payment date.

ARTICLE III.
TAXATION AND TAX WITHHOLDING

3.1Representation. Participant represents to the Company that Participant has reviewed with Participant’s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.

4

3.2Tax Withholding.

(a)The Company has the right and option, but not the obligation, to treat Participant’s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the PSUs as Participant’s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Award.

(b)Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the PSUs, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the PSUs. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the PSUs or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the PSUs to reduce or eliminate Participant’s tax liability.

3.3Section 409A. The provisions of Section 10.6 of the Plan are incorporated by reference herein as if fully set forth herein.

ARTICLE IVOTHER PROVISIONS

4.1Adjustments. Participant acknowledges that the PSUs, and the Shares subject to the PSUs, are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.

4.2Forfeiture and Claw-Back. Participant acknowledges and agrees that the PSUs (including any proceeds, gains or other economic benefit actually or constructively received by Participant upon any receipt PSUs) shall be subject to the provisions of any claw-back policy implemented by the Company or any Subsidiary, including, without limitation, any claw-back policy adopted to comply with the requirements of applicable law, including without limitation the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder.

4.3Notices. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company’s Secretary at the Company’s principal office or the Secretary’s then-current email address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the Designated Beneficiary) at Participant’s last known mailing address, email address or facsimile number in the Company’s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.

4.4Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.

4.5Conformity to Securities Laws. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws.

5

4.6Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in this Agreement or the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.

4.7Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan or this Agreement, if Participant is a Section 16 Person, the Plan, the Grant Notice, this Agreement and the PSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.

4.8Entire Agreement. The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.

4.9Agreement Severable. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.

4.10Limitation on Participant’s Rights. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the PSUs, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the PSUs, as and when settled pursuant to the terms of this Agreement.

4.11Not a Contract of Employment. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.

4.12Counterparts. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.

4.13Restrictions. In the event the Shares are no longer registered with the United States Securities and Exchange Commission (as determined by the Administrator), any Shares acquired in respect of the PSUs shall be subject to such terms and conditions as the Administrator shall determine, including, without limitation, restrictions on the transferability, repurchase rights, the right of the Company to require that Shares be transferred in the event of certain transactions, rights of first refusal, tag-along rights, bring-along rights, redemption and co-sale rights and voting requirements. Such terms and conditions may be additional to those contained in the Plan and may, as determined by the Administrator, be contained in an exercise notice, securityholders’ agreement or in such other agreement as the Administrator shall determine, in each case in a form determined by the Administrator. The Administrator may condition the issuance of such Shares on Participant’s consent to such terms and conditions and Participant’s entering into such agreement or agreements.

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Soroush Salehian Dardashti, certify that:

1.I have reviewed this Quarterly Report of Aeva Technologies, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2024	By:	/s/ Soroush Salehian Dardashti
		Soroush Salehian Dardashti
		Chief Executive Officer and Director (Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Saurabh Sinha, certify that:

1.I have reviewed this Quarterly Report of Aeva Technologies, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2024	By:	/s/ Saurabh Sinha
		Saurabh Sinha
		Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Aeva Technologies, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 8, 2024	By:	/s/ Soroush Salehian Dardashti
		Soroush Salehian Dardashti
		Chief Executive Officer and Director (Principal Executive Officer)

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Aeva Technologies, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 8, 2024	By:	/s/ Saurabh Sinha
		Saurabh Sinha
		Chief Financial Officer (Principal Financial and Accounting Officer)

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2024	Apr. 25, 2024
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Registrant Name	AEVA TECHNOLOGIES, INC.
Entity Central Index Key	0001789029
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-39204
Entity Tax Identification Number	84-3080757
Entity Address, Address Line One	555 Ellis Street
Entity Address, City or Town	Mountain View
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94043
City Area Code	650
Local Phone Number	481-7070
Entity Common Stock, Shares Outstanding		52,847,027
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Common Stock [Member]
Document Information [Line Items]
Trading Symbol	AEVA
Title of 12(b) Security	Common stock, $0.0001 par value per share
Security Exchange Name	NYSE
Warrant [Member]
Document Information [Line Items]
Trading Symbol	AEVA.WS
Title of 12(b) Security	Warrants to purchase one share of common stock
Security Exchange Name	NYSE

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets
Cash and cash equivalents	$ 29,605	$ 38,547
Marketable securities	159,723	182,481
Accounts receivable	978	628
Inventories	2,163	2,374
Other current assets	4,882	5,195
Total current assets	197,351	229,225
Operating lease right-of-use assets	6,444	7,289
Property, plant and equipment, net	12,552	12,114
Intangible assets, net	2,400	2,625
Other noncurrent assets	6,062	6,132
Total assets	224,809	257,385
Liabilities and stockholders' equity
Accounts payable	3,424	3,602
Accrued liabilities	2,639	2,648
Accrued employee costs	2,443	6,043
Lease liability, current portion	3,681	3,587
Other current liabilities	4,406	2,524
Total current liabilities	16,593	18,404
Lease liability, noncurrent portion	2,807	3,767
Warrant liability	7,209	6,772
Total liabilities	26,609	28,943
Commitments and contingencies (Note 14)
Convertible preferred stock $0.0001 par value; 10,000 shares authorized; no,shares issued and outstanding	0	0
Stockholders' Deficit
Common stock $0.0001 par value; 422,000 shares authorized; 52,816and 52,389 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	5	5
Additional paid-in capital	693,369	688,124
Accumulated other comprehensive loss	(248)	(87)
Accumulated deficit	(494,926)	(459,600)
Total stockholders' equity	198,200	228,442
Total liabilities and stockholders' equity	$ 224,809	$ 257,385

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	422,000,000	422,000,000
Common stock, shares issued	52,816,000	52,389,000
Common stock, shares outstanding	52,816,000	52,389,000
Convertible Preferred Stock [Member]
Temporary equity, par value per share	$ 0.0001	$ 0.0001
Temporary equity, shares authorized	10,000,000	10,000,000
Temporary equity, shares issued	0	0
Temporary equity, shares outstanding	0	0

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 2,107	$ 1,148
Cost of revenue	3,499	2,529
Gross loss	(1,392)	(1,381)
Research and development expenses	25,012	25,454
General and administrative expenses	8,411	7,833
Selling and marketing expenses	2,529	2,598
Total operating expenses	35,952	35,885
Operating loss	(37,344)	(37,266)
Interest income	2,458	2,064
Other income (expense), net	(439)	28
Loss before income taxes	(35,326)	(35,174)
Income tax provision	0	0
Net loss	(35,326)	(35,174)
Unrealized gain (loss) on available-for-sale securities	(161)	1,212
Total comprehensive loss	$ (35,487)	$ (33,962)
Net loss per share, Basic	$ (0.67)	$ (0.8)
Net loss per share, Diluted	$ (0.67)	$ (0.8)
Weighted average shares of common stock outstanding - Basic	52,742,725	43,925,565
Weighted-average shares used in computing net loss per share - diluted	52,742,725	43,925,565

XML

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated other comprehensive loss	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2022	$ 329,926	$ 4	$ 643,774	$ (3,585)	$ (310,267)
Beginning balance, Shares at Dec. 31, 2022		43,749,685
Share-based compensation	5,963		5,963
Issuance of common stock upon exercise of stock options	57		57
Issuance of common stock upon exercise of stock options, Shares		47,328
Issuance of common stock upon release of restricted stock units, Shares		215,505
Shares withheld for the withholding tax on vesting of restricted stock	(20)		(20)
Shares withheld for the withholding tax on vesting of restricted stock, Shares		(2,499)
Unrealized gain (loss) on available-for-sale securities	1,212			1,212
Net Income (Loss)	(35,174)				(35,174)
Ending balance at Mar. 31, 2023	301,964	$ 4	649,774	(2,373)	(345,441)
Ending balance, Shares at Mar. 31, 2023		44,010,019
Beginning balance at Dec. 31, 2023	228,442	$ 5	688,124	(87)	(459,600)
Beginning balance, Shares at Dec. 31, 2023		52,388,961
Share-based compensation	5,261		5,261
Issuance of common stock upon exercise of stock options	$ 39		39
Issuance of common stock upon exercise of stock options, Shares	28,227	28,227
Issuance of common stock upon release of restricted stock units, Shares		423,869
Shares withheld for the withholding tax on vesting of restricted stock	$ (55)		(55)
Shares withheld for the withholding tax on vesting of restricted stock, Shares		(25,286)
Unrealized gain (loss) on available-for-sale securities	(161)			(161)
Net Income (Loss)	(35,326)				(35,326)
Ending balance at Mar. 31, 2024	$ 198,200	$ 5	$ 693,369	$ (248)	$ (494,926)
Ending balance, Shares at Mar. 31, 2024		52,815,771

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (35,326)	$ (35,174)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,345	955
Impairment of inventories	465	45
Change in fair value of warrant liability	437	(28)
Stock-based compensation	5,261	5,963
Amortization of right-of-use assets	845	744
Amortization of premium and accretion of discount on available-for-sale securities, net	(1,087)	(632)
Changes in operating assets and liabilities:
Accounts receivable	(350)	442
Inventories	(251)	(100)
Other current assets	312	790
Other noncurrent assets	70	0
Accounts payable	(89)	(1,749)
Accrued liabilities	(10)	(5,207)
Accrued employee costs	(3,600)	(1,307)
Lease liability	(866)	(754)
Other current liabilities	1,882	0
Net cash used in operating activities	(30,962)	(36,012)
Cash flows from investing activities:
Purchase of property, plant and equipment	(1,648)	(1,275)
Purchase of available-for-sale securities	(38,881)	(54,520)
Proceeds from maturities of available-for-sale securities	62,565	56,214
Net cash provided by investing activities	22,036	419
Cash flows from financing activities:
Payments of taxes withheld on net settled vesting of restricted stock units	(55)	(20)
Proceeds from exercise of stock options	39	57
Net cash provided by (used in) financing activities	(16)	37
Net decrease in cash and cash equivalents	(8,942)	(35,556)
Beginning cash and cash equivalents	38,547	67,420
Ending cash and cash equivalents	29,605	31,864
Supplemental disclosures of cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplemental disclosures of non-cash investing and financing activities:
Unpaid property, plant and equipment purchases	$ 0	$ 503

XML

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (35,326)	$ (35,174)

XML

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non Rule 10b5-1 Arrangement Modified	false

XML

Description of Business and Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Description of Business and Summary of Significant Accounting Policies

Note 1. Description of Business and Summary of Significant Accounting Policies

Description of Business

Aeva Technologies, Inc. (the “Company”), through its Frequency Modulated Continuous Wave (“FMCW”) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation and security application.

The Company’s common stock and warrants are listed on the New York Stock Exchange stock market under the symbols “AEVA” and "AEVA.WS".

Basis of Presentation and Unaudited Interim Financial Statements

The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.

The accompanying condensed consolidated financial statements are unaudited and have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period.

These condensed consolidated financial statements and other information presented in this Form 10-Q should be read in conjunction with the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC.

On March 18, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s shares of common stock, $0.0001 par value (the “Common Stock”). Pursuant to the Reverse Stock Split, every five (5) shares of issued and outstanding shares of common stock were combined into one (1) share of common stock. Accordingly, unless we indicate otherwise, all the current period and historical per share data, number of shares issued and outstanding, stock awards, and other common stock equivalents for the periods presented in this Interim Report on Form 10-Q have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. There was no change to the shares authorized or in the par value per share of common stock of $0.0001.

The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity. The Company did not issue fractional shares in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to fractional shares of common stock were instead entitled to receive a proportional cash payment. The number of shares of common stock issuable under our equity incentive plans and exercisable under the outstanding warrants were also proportionately adjusted.

Principles of Consolidation and Liquidity

The condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

The Company has funded its operations primarily through the Business Combination (the “Business Combination”) with InterPrivate Acquisition Corp. (the Company’s predecessor, which was originally incorporated in Delaware as a special purpose acquisition company (“IPV”)) on March 12, 2021, and issuances of stock. As of March 31, 2024, the Company’s existing sources of liquidity included cash and cash equivalents and marketable securities of $189.3 million. The Company has a limited history of operations and has incurred negative cash flows from operating activities and losses from operations in the past as reflected in the accumulated deficit of $494.9 million as of March 31, 2024. The Company expects to continue to incur operating losses due to the investments it intends to make in its business, including product development. Management believes that existing cash and cash equivalents and marketable securities will be sufficient to fund operating and capital expenditure requirements through at least 12 months from the date of issuance of these financial statements.

Significant Risks and Uncertainties

The Company is subject to those risks common in the technology industry and also those risks common to early stage companies including, but not limited to, the possibility of not being able to successfully develop or market its products, technological obsolescence, competition, dependence on key personnel and key external alliances, the successful protection of its proprietary technologies, compliance with government regulations, and the possibility of not being able to obtain additional financing when needed.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and trade receivables. The Company maintains the majority of its cash and cash equivalents in accounts with large financial institutions. At times, balances in these accounts may exceed federally insured limits; however, to date, the Company has not incurred any losses on its deposits of cash and cash equivalents and believes the exposure to risk of loss is not material. Risks associated with the Company’s marketable securities is mitigated by investing in investment-grade rated securities when purchased.

The Company’s accounts receivable are derived from customers located in the United States, APAC, and Europe. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers’ financial conditions and requires customer advance payments in certain circumstances.

As of March 31, 2024, three customers accounted for 44%, 15% and 12% of the accounts receivable, respectively. As of December 31, 2023, one customer accounted for 42% of accounts receivable. As of March 31, 2024, one vendor accounted for 10% of the accounts payable. As of December 31, 2023, three vendors accounted for 12%, 11% and 11% each of the accounts payable, respectively.

Recent Accounting Pronouncements

In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280):Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company does not expect ASU 2023-07 to have a material impact on the Company's financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our consolidated financial statements and related disclosures.

XML

Revenue

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Revenue

Note 2. Revenue

Disaggregation of Revenues

The Company disaggregates its revenue from contracts with customers by geographic region based on the primary billing address of the customer and timing of transfer of goods or services to customers (point-in-time or over time), as it believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. Total revenue for the three months ended March 31, 2024 and 2023, based on the disaggregation criteria described above were as follows (in thousands):

	Three Months Ended March 31,
	2024					2023
	Revenue		% of Revenue			Revenue		% of Revenue
Revenue by primary geographical market:
North America	$	1,674		79	%	$	730		64	%
EMEA		229		11	%		244		21	%
Asia		204		10	%		174		15	%
Total	$	2,107		100	%	$	1,148		100	%
Revenue by timing of recognition:
Recognized at a point in time	$	1,714		81	%	$	947		82	%
Recognized over time		393		19	%		201		18	%
Total	$	2,107		100	%	$	1,148		100	%

For the three months ended March 31, 2024, two customers accounted for 39% and 36% of the Company’s revenue, respectively. For the three months ended March 31, 2023, three customers accounted for 20%, 19% and 17% of the Company’s revenue, respectively.

Contract Assets and Contract Liabilities

As of March 31, 2024, and December 31, 2023, the Company had contract assets of $0.1 million and $0.1 million, respectively, recognized in other current assets. As of March 31, 2024, and December 31, 2023, the Company had contract liabilities of $3.6 million and $2.1 million, respectively, recognized in other current liabilities.

XML

Financial Instruments

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Financial Instruments

Note 3. Financial Instruments

The following tables summarize the Company’s financial assets and liabilities measured at fair value by level within the fair value hierarchy:

	March 31, 2024
	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalent		Marketable Securities
	(in thousands)
Assets
Cash	$	17,668	$	—	$	—		$	17,668	$	17,668	$	—
Level 1
Money market funds		264		—		—			264		264		—
Level 2
U.S. agency securities		27,635		2		(76	)		27,561		—		27,561
U.S. Treasury securities		30,255		—		(41	)		30,214		11,673		18,541
Commercial paper		42,591		6		(45	)		42,552		—		42,552
Corporate bonds		71,163		20		(114	)		71,069		—		71,069
Subtotal		171,644		28		(276	)		171,396		11,673		159,723
Total assets	$	189,576	$	28	$	(276	)	$	189,328	$	29,605	$	159,723
Liabilities
Level 3
Warrant liabilities		7,209		—		—			7,209		—		—
Total liabilities	$	7,209	$	—	$	—		$	7,209	$	—	$	—

	December 31, 2023
	Adjusted Cost		Unrealized Gain		Unrealized Losses			Fair Value		Cash and Cash Equivalent		Marketable Securities
	(in thousands)
Assets
Cash	$	21,799	$	—	$	—		$	21,799	$	21,799	$	—
Level 1
Money market funds		6,266		—		—			6,266		6,266		—
Level 2
U.S. Government securities		35,962		8		(97	)		35,873		—		35,873
U.S. Treasury securities		18,323		1		(14	)		18,310		10,482		7,828
Commercial paper		38,491		25		(16	)		38,500		—		38,500
Corporate bonds		100,274		136		(130	)		100,280		—		100,280
Subtotal		193,050		170		(257	)		192,963		10,482		182,481
Total assets	$	221,115	$	170	$	(257	)	$	221,028	$	38,547	$	182,481
Liabilities
Level 3
Warrant liabilities		6,772		—		—			6,772		—		—
Total liabilities	$	6,772	$	—	$	—		$	6,772	$	—	$	—

The fair value of the private placement and Series A warrant liabilities is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. In determining the fair value of the warrant liabilities, the Company used the Black-Scholes option-pricing model to estimate the fair value using unobservable inputs including the expected term, expected volatility, risk-free interest rate, and dividend yield.

The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments (in thousand):

	March 31, 2024			December 31, 2023
Fair value, beginning balance	$	6,772		$	90
Fair value at issuance of Series A warrants		—		$	6,450
Change in the fair value of Series A warrants included in other income (expense), net		450		$	300
Change in the fair value of private placement warrants included in other income (expense), net		(13	)		(68	)
Fair value, closing balance	$	7,209		$	6,772

The key inputs into the Black-Scholes option pricing model for the private warrants were as follows for the relevant periods:

	March 31, 2024			December 31, 2023
Expected term (years)		2.0			2.2
Expected volatility		90.3	%		94.1	%
Risk-free interest rate		5.03	%		4.23	%
Dividend yield		0	%		0	%
Exercise Price	$	57.50		$	57.50

The key inputs into the Black-Scholes option pricing model for the Series A warrants were as follows for the relevant periods:

	March 31, 2024			December 31, 2023
Expected term (years)		3.7			4.0
Expected volatility		92.1	%		87.2	%
Risk-free interest rate		4.29	%		3.89	%
Dividend yield		0	%		0	%
Exercise Price	$	5.00		$	5.00

XML

Acquisition and Intangible Assets

3 Months Ended

Mar. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Acquisition and Intangible Assets

Note 4. Acquisition of Intangible Assets

As of March 31, 2024, expected amortization expense relating to purchased intangible assets was as follows (in thousands):

Remainder of 2024	$	675
2025		900
2026		825
Total future amortization	$	2,400

The Company recorded amortization expense related to the acquired intangible assets of $0.2 million each for the three months ended March 31, 2024 and March 31, 2023, respectively.

XML

Inventories

3 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

Inventories

Note 5. Inventories

Inventories consisted of the following (in thousands):

	March 31,		December 31,
	2024		2023
Raw materials	$	1,583	$	2,178
Work-in-progress		60		136
Finished goods		520		60
Total inventories	$	2,163	$	2,374

XML

Property, Plant and Equipment

3 Months Ended

Mar. 31, 2024

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Note 6. Property, Plant and Equipment

Property, plant and equipment consisted of the following (in thousands):

	March 31,			December 31,
	2024			2023
Computer equipment	$	2,944		$	2,795
Lab equipment		7,255			7,151
Leasehold improvements		3,312			3,148
Construction in progress		700			1,434
Testing equipment		1,752			1,455
Manufacturing equipment		5,743			4,269
Furniture, fixtures and other equipment		561			458
Total property, plant and equipment	$	22,268		$	20,710
Less: accumulated depreciation		(9,716	)		(8,596	)
Total property, plant and equipment, net	$	12,552		$	12,114

Depreciation related to property, plant, and equipment was $1.1 million and $0.7 million for the three months ended March 31, 2024 and March 31, 2023, respectively.

XML

Other Current Assets

3 Months Ended

Mar. 31, 2024

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Current Assets

Note 7. Other current assets

Other current assets consisted of the following (in thousands):

	March 31,		December 31,
	2024		2023
Prepaid expenses	$	2,222	$	2,228
Contract assets		111		140
Vendor deposits		975		1,104
Other current assets		1,574		1,723
Total other current assets	$	4,882	$	5,195

XML

Other Non-Current Assets

3 Months Ended

Mar. 31, 2024

Other Assets, Noncurrent [Abstract]

Other non-current assets

Note 8. Other non-current assets

Other non-current assets consist of the following (in thousands):

	March 31,		December 31,
	2024		2023
Non marketable equity investments	$	5,000	$	5,000
Security deposit		1,062	$	1,116
Other non-current assets		—		16
Total other non-current assets	$	6,062	$	6,132

In November 2023, the Company made an investment in 700,440 Preferred Stock of a private company for a cash consideration of $5.0 million, which is classified as non-marketable equity investment. The Company’s investment in the private company represents less than 1% of total capitalization. The Company neither has significant influence over the private company nor does the investment amount to a controlling financial interest in the private company. The Company elected to apply the measurement alternative, and as such, records the investment at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes in orderly transactions. During the period ended March 31, 2024, the Company did not identify any impairment or observable price changes for this non-marketable equity investment.

XML

Financing Transaction

3 Months Ended

Mar. 31, 2024

Warrants and Rights Note Disclosure [Abstract]

Financing transaction

Note 9. Financing transaction

Private Investment

On November 8, 2023, the Company entered into Subscription Agreements (the “Subscription Agreements”) with entities affiliated with Sylebra Capital Limited (“Sylebra”) and Adage Capital Management, providing for the purchase of an aggregate of 7,360,460 shares of the Company’s common stock, $0.0001 par value per share (the “PIPE Shares”), at a price of $2.90 per PIPE Share for an aggregate purchase price of approximately $21.4 million (the “Private Placement”). The PIPE Shares are recorded as outstanding common stock.

Standby Equity Purchase Agreement

On November 8, 2023, the Company also entered into a Standby Equity Purchase Agreement (the “Facility Agreement”) with entities affiliated with Sylebra, pursuant to which the Company will have the right, but not the obligation to sell to Sylebra up to $125 million of its shares of Preferred Stock, subject to satisfaction of certain conditions, by November 8, 2026. Each sale the Company requests under the Facility Agreement (each, an “Advance” and collectively, the “Advances”) may be for a number of shares of preferred stock with an aggregate value of at least $25.0 million but not more than $50.0 million (except with Sylebra’s consent).

When and if issued, the preferred stock will be issued at a price per share of $10,000. Holders of the preferred stock will be entitled to a quarterly dividend at the rate of 7.0% per annum payable in cash or in kind at the option of the Company. The preferred stock will have an initial liquidation preference of $12,000 per share, plus accrued dividends. The preferred stock will have no voting rights as a class or series except in such instances as required by Delaware law or certain matters enumerated in the facility agreement related to the protection of the preferred stock.

The preferred stock will be convertible at the option of the holders into the number of shares of Common Stock equal to $10,000 divided by the then-applicable conversion price. At any time after the two year anniversary of any issuance of any series of preferred stock, the Company will have the option to convert all (but not less than all) of any series of then-outstanding preferred stock by paying a make-whole payment, in either stock or cash, equal to three years of dividends, provided that the closing price of the Common Stock exceeds 250% of the then-applicable conversion price for at least 20 out of 30 consecutive trading days prior to the date of conversion. To the extent, if any, a conversion would result in the holder thereof becoming the beneficial owner of more than 19.9% of the Company’s outstanding Common Stock, the Company will issue the Investor Pre-Funded Warrant in the form attached to the Facility Agreement. The preferred stock will be subject to customary pre-emptive rights.

The Company’s right to request Advances is conditioned upon the Company achieving a minimum of one new passenger auto-original equipment manufacturer (“OEM”) or commercial OEM program award with at least a 50,000 unit volume, the trading price of the Common Stock being below $15 at the time of the Advance request and other customary conditions. Prior to any Advance, the Company will assess its capital needs and other factors, including the impact of an Advance on the Company’s outstanding executive pledge arrangements.

The Preferred Stock issued in connection with the facility agreement ranks senior to common stock upon the Company’s liquidation, dissolution or winding up. The Preferred Stock is entitled to priority cumulative dividends which shall accrue daily from and after the original issue date of such share and shall compound on a quarterly basis on each dividend payment date. The accrued dividends shall in all cases be payable upon liquidation.

The Company shall pay dividends on each share of Preferred Stock in cash or in kind through issuance of shares of common stock with an aggregate value equal to the amount of the dividend to have been paid divided by the dividend conversion price. The board of directors of the Company may at its sole discretion elect to pay the dividends in cash in lieu of shares of common stock. The Convertible Redeemable Preferred Stock have no voting rights unless they are converted into shares of common stock.

Holders may, at their option, elect to convert some or all Preferred Stock held by such holder, at any time and from time to time prior to a change of control, into a number of shares of common stock per share of the Preferred Stock equal to (x) the quotient of the issuance price divided by the conversion price in effect at the time of conversion. At any time on or after the two-year anniversary of the issuance date, the Company shall have the right to redeem the Preferred Stock of any holder outstanding at such time at the issuance price plus three (3) years of dividend payment (“Redemption price”); provided, that (a) the closing price of a share of common stock exceeds 250% of the then-applicable conversion price per share for at least 20 out of 30 consecutive trading days prior to the redemption date and (b) a shelf registration statement that is required to be effective pursuant to the registration rights agreement on such date shall be effective on such date with respect to the applicable holder. The redemption price shall be payable in cash or in shares of common stock. Additionally, upon the occurrence of a change of control, the holders of Preferred Stock shall be entitled to receive in full a liquidating purchase in cash and in the amount per share of the Preferred Stock equal to the sum of (i) the liquidation preference plus (ii) accrued dividends with respect to such shares of Preferred Stock.

In connection with this financing, the Company also paid the entities affiliated with Sylebra, (a) a facility fee in the amount of $2.5 million, (b) an origination fee in the amount of $0.6 million, (c) an administrative fee in the amount of $0.3 million and (d) fees and expenses of the investor and its counsel, of approximately $0.4 million. The issuance costs related to the Facility Agreement were expensed as incurred as it failed to meet the equity classification guidance under ASC 815-40, and were deemed to be a derivative asset. The fair value of the derivative asset was not material as of and for the period ended March 31, 2024.

In addition, upon receipt of stockholder approval in December 2023, the Company issued to Sylebra 3,000,000 Series A Warrants to purchase shares of Common Stock at an exercise price of $5.00.

As of March 31, 2024, the Company had 3,000,000 Series A Warrants outstanding. The Series A Warrants were issued as consideration for entering into the Facility Agreement as discussed above. Each Series A Warrant entitles the holder to purchase one share of the Company’s common stock at a price of $5.00 per share. Each Series A Warrant is currently exercisable and expires in December 2027. Holders shall not have the right to exercise the Series A Warrants to the extent that after giving effect to such exercise, such person would beneficially own in excess of 19.9% of the Company’s outstanding common stock immediately after giving effect to such exercise.

The exercise price and number of shares of common stock issuable upon exercise of the Series A Warrants may be adjusted in certain circumstances including in the event of a stock dividend or split, subsequent rights offerings, pro rata purchases, merger, reorganization, recapitalization, or spin-off. However, the Series A Warrants will not be adjusted for issuances of shares of common stock at a price below their respective exercise prices. The Series A Warrants do not entitle the holders to any voting rights, dividends or other rights as a stockholder of the Company prior to being exercised for common stock.

The Company analyzed the Series A Warrants and determined that they are freestanding and do not exhibit any of the characteristics within ASC 480, and as such do not meet the characteristics of a liability under ASC 480. However, Series A Warrants do not meet all requirements for equity classification under ASC 815, and therefore are classified as a liability on the Company’s consolidated balance sheets.

XML

Capital Structure

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

Capital Structure

Note 10. Capital Structure

As of March 31, 2024, the Company was authorized to issue up to 422,000,000 shares of common stock, each with a par value of $0.0001 per share.

Preferred Stock

As of March 31, 2024, the Company was authorized to issue up to 10,000,000 shares of preferred stock, each with a par value of $0.0001 per share. As of March 31, 2024 and December 31, 2023, no shares of preferred stock were issued and outstanding.

Warrants

As of March 31, 2024, the Company had 2,414,975 public and 76,800 private warrants outstanding. Each warrant entitles the registered holder to purchase one share of common stock at a price of $57.50 per share. Additionally, the Company also issued 3,000,000 Series A Warrants issued in connection with the facility agreement. Each Series A Warrants entitles the registered holder to purchase one share of common stock at an exercise price of $5.00 per share.

XML

Earnings (Loss) Per Share

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

Note 11. Earnings (Loss) Per Share

The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except per share data):

	Three Months Ended March 31,
	2024			2023
Numerator:
Net loss attributable to common stockholders	$	(35,326	)	$	(35,174	)
Denominator:
Weighted average shares of common stock outstanding — Basic and Diluted		52,742,725			43,925,565
Net loss per share attributable to common stockholders — Basic and Diluted	$	(0.67	)	$	(0.80	)

The following table presents the potential common shares outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been anti-dilutive:

	Three Months Ended March 31,
	2024		2023
Common stock options issued and outstanding		2,386,503		2,634,606
Restricted stock units		5,484,398		4,348,913
Performance-based restricted stock units		1,911,765		—
Common stock warrants		2,491,775		2,491,775
Series A warrants		3,000,000		—
Total		15,274,441		9,475,294

XML

Stock-based Compensation

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Stock-based Compensation

Note 12. Stock-based Compensation

Stock Options

The Company maintains the 2016 Stock Incentive Plan and the 2021 Incentive Award Plan (the “Stock Plans”) under which incentive stock options, non-qualified stock options and restricted stock units (“RSU”) may be granted to employees. Under the Stock Plans, the Company has 3,677,480 shares available for issuance as of March 31, 2024.

Under the terms of the Stock Plans, incentive stock options must have an exercise price at or above the fair market value of the stock on the date of the grant, while non-qualified stock options are permitted to be granted below fair market value of the stock on the date of grant. The majority of stock options granted have service-based vesting conditions only. The service-based vesting conditions vary, typically stock options vest over four years with 25% of stock options vesting on the first anniversary of the grant and the remaining 75% vesting monthly over the remaining 36 months. Option holders have a ten-year period to exercise the options before they expire.

A summary of the Company’s stock option activity, for three months ended March 31, 2024, was as follows:

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2023		2,414,730		$	2.79		5.73	$	4,004
Granted		—			—		—		—
Exercised		(28,227	)		1.37		—		—
Forfeited		—			—		—		—
Outstanding as of March 31, 2024		2,386,503		$	2.81		5.49	$	4,253
Vested and exercisable as of March 31, 2024		2,317,344		$	2.46		5.42	$	4,251
Vested and expected to vest as of March 31, 2024		2,386,503		$	2.81		5.49	$	4,253

There were no options granted during the three months ended March 31, 2024. As of March 31, 2024, the Company had $0.5 million of unrecognized stock-based compensation expense related to the stock options. This cost is expected to be recognized over a weighted-average period of 1.65 years.

Restricted Stock Units (“RSUs”) and Performance-based Restricted Stock Units (“PBRSUs”)

In May 2023, the Company granted a total of 1,176,471 PBRSUs to certain executives that vest on achieving certain operational milestones as defined in the individual grant agreements subject to continued employment through 2025. Stock-based compensation expense is recognized over the expected performance achievement period of individual performance milestones when the achievement of each individual performance milestone becomes probable. If satisfaction of the performance condition is not probable, stock-based compensation cost recognition is deferred until it becomes probable. The Company reassesses the probability as to whether satisfaction of the performance condition is probable on a quarterly basis, and stock-based compensation cost is adjusted based on the portion of the requisite service provided. These PBRSUs neither carry rights to dividends nor voting rights until the shares are issued or transferred to the recipient. Awards are forfeited if an employee leaves the Company before the PBRSUs vest or the performance period lapses. The weighted-average grant date PBRSU fair value of $5.10 per share is determined based upon the market closing price of the Company’s common stock on the date of grant. As of March 31, 2024, the total unrecognized compensation expense related to the performance-based PBRSUs was $1.3 million, which is expected to be amortized over a weighted-average period of 1.8 years.

In May 2023, the Company also granted a total of 735,294 market-based PBRSUs to certain executives that vest over a multi-year period, upon continued service and when the volume-weighted average price per share (“WVAP Average”) of the Company’s common stock for the preceding 30 consecutive trading days equals or exceeds the target stock price for the indicated year. The Company recognizes stock-based compensation based upon the grant date fair value on an accelerated attribution basis over the requisite service period of the award. Provided that the requisite service is rendered, the total fair value of the market-based PBRSUs at the date of grant is recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the achievement of the specified market criteria. These PBRSUs neither carry rights to dividends nor voting rights until the shares are issued or transferred to the recipient. Awards are forfeited if an employee leaves the Company before the PBRSUs vest. The weighted-average grant date fair value of the market-based PBRSUs was $1.40 per share. The Company estimated the fair value of the market-based PBRSUs award on the grant date using the Monte Carlo simulation model with the following assumptions:

Expected term (years)	0.5 - 4.7
Expected volatility		70.9	%
Risk-free interest rate		3.29	%
Dividend yield		0	%
Share price	$	5.10

As of March 31, 2024, the total unrecognized compensation expense related to the market-based PBRSUs was $0.7 million, which is expected to be amortized over a weighted-average period of 3 years.

The following table summarizes our RSU activity for the three months ended March 31, 2024:

	Shares			Weighted Average Grant Date Fair Value per Share
Outstanding as of December 31, 2023		5,204,177		$	9.65
Granted		889,257			5.05
Released		(398,583	)		12.91
Forfeited		(210,453	)		8.83
Outstanding as of March 31, 2024		5,484,398		$	8.69

As of March 31, 2024, the Company had $39.6 million of unrecognized stock-based compensation expense related to the RSUs. This cost is expected to be recognized over a weighted-average period of 2.90 years. The above table excludes 1,911,765 PBRSUs granted to certain executive officers during the year ended December 31, 2023, and are outstanding as of March 31, 2024.

Compensation expense

Total stock-based compensation expense by function was as follows (in thousands):

	Three Months Ended March 31,
	2024		2023
Cost of revenue	$	102	$	330
Research and development expenses		3,989		4,410
General and administrative expenses		907		1,119
Sales and marketing expenses		263		104
Total	$	5,261	$	5,963

XML

Income Taxes

3 Months Ended

Mar. 31, 2024

Income Tax Disclosure [Abstract]

Income Taxes

Note 13. Income Taxes

There has historically been no federal or state provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. For the three months ended March 31, 2024 and 2023, the Company recognized no provision for income taxes.

The federal and state net operating loss carryforwards may be subject to significant limitations under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and similar provisions under state law. The Tax Reform Act of 1986 contains provisions that limit the federal net operating loss carryforwards that may be used in any given year in the event of special occurrences, including significant ownership changes. The Company has completed an analysis as of December 31, 2022 and doesn’t expect any net operating loss carryforwards or tax credit carryforwards to expire due to a limitation.

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 14. Commitments and Contingencies

Leases

The weighted-average remaining lease terms were 1.9 years and 2.0 years as of March 31, 2024 and December 31, 2023, respectively. The weighted-average discount rates were 6.32% and 6.04% as of March 31, 2024 and December 31, 2023, respectively. Operating lease cost for three months ended March 31, 2024 and 2023, was $1.0 million and $0.8 million, respectively.

The following is a maturity analysis of the annual undiscounted cash flows reconciled to the carrying value of the operating lease liabilities as of March 31, 2024 (in thousands):

	Operating Leases
Remainder of 2024	$	2,974
2025		3,157
2026		729
Total minimum lease payments		6,860
Less: imputed interest		(372	)
Total lease liability	$	6,488

Litigation

From time to time, the Company is involved in actions, claims, suits, and other proceedings in the ordinary course of business, including assertions by third parties relating to intellectual property infringement, breaches of contract or warranties, or employment-related matters. When it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated, the Company records a liability for such loss contingencies. The Company’s estimates regarding potential losses and materiality are based on the Company’s judgment and assessment of the claims utilizing currently available information. Although the Company will continue to reassess its reserves and estimates based on future developments, the Company’s objective assessment of the legal merits of such claims may not always be predictive of the outcome and actual results may vary from the Company’s current estimates.

Litigation – other matters

On March 7, 2024, a putative class action lawsuit was filed in the Court of Chancery of the State of Delaware against InterPrivate Acquisition Management LLC, InterPrivate LLC, and former directors and officers of InterPrivate Acquisition Corp (“IPV”). The lawsuit is captioned, Louis Smith v. Ahmed M. Fattouh, et al., (Del. Ch. 2024). Among other remedies, the complaint seeks damages and attorneys’ fees and costs. In connection with IPV’s March 12, 2021, merger transaction with Aeva Inc., Aeva granted certain indemnification rights to IPV’s former directors and officers. However, neither Aeva nor its current directors or officers are named as defendants in the complaint.

Indemnifications

In the ordinary course of business, the Company is not subject to potential obligations under guarantees that fall within the scope of FASB ASC Guarantees, (Topic 460), except for standard indemnification provisions that are contained within many of the Company’s customer agreements and give rise only to disclosure requirements prescribed by Topic 460. Indemnification provisions contained within the Company’s customer agreements are generally consistent with those prevalent in the Company’s industry. The Company has not incurred any obligations under customer indemnification provisions and does not expect to incur significant obligations in the future. Accordingly, the Company does not maintain accruals for potential customer indemnification obligations.

XML

Segment Information

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Segment Information

Note 15. Segment Information

The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision-maker (“CODM”), consisting of the Company’s chief executive officer and the Company’s chief technology officer as a group, in deciding how to allocate resources and assess the Company’s financial and operational performance. In addition, the Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. As a result, the Company has determined that the Company’s business operates in a single operating segment. Since the Company operates as one operating segment, all required financial segment information can be found in the financial statements.

Long-Lived Assets

The following table sets forth the Company’s property, plant, and equipment, net by geographic region (in thousands):

	March 31,		December 31,
	2024		2023
North America	$	8,580	$	8,675
Asia		3,657		3,154
Others		315		285
Total	$	12,552	$	12,114

XML

Description of Business and Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Description of Business

Description of Business

Aeva Technologies, Inc. (the “Company”), through its Frequency Modulated Continuous Wave (“FMCW”) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation and security application.

The Company’s common stock and warrants are listed on the New York Stock Exchange stock market under the symbols “AEVA” and "AEVA.WS".

Basis of Presentation and Unaudited Interim Financial Statements

Basis of Presentation and Unaudited Interim Financial Statements

The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.

The accompanying condensed consolidated financial statements are unaudited and have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period.

These condensed consolidated financial statements and other information presented in this Form 10-Q should be read in conjunction with the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC.

On March 18, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s shares of common stock, $0.0001 par value (the “Common Stock”). Pursuant to the Reverse Stock Split, every five (5) shares of issued and outstanding shares of common stock were combined into one (1) share of common stock. Accordingly, unless we indicate otherwise, all the current period and historical per share data, number of shares issued and outstanding, stock awards, and other common stock equivalents for the periods presented in this Interim Report on Form 10-Q have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. There was no change to the shares authorized or in the par value per share of common stock of $0.0001.

The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity. The Company did not issue fractional shares in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to fractional shares of common stock were instead entitled to receive a proportional cash payment. The number of shares of common stock issuable under our equity incentive plans and exercisable under the outstanding warrants were also proportionately adjusted.

Principles of Consolidation and Liquidity

Principles of Consolidation and Liquidity

The condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

The Company has funded its operations primarily through the Business Combination (the “Business Combination”) with InterPrivate Acquisition Corp. (the Company’s predecessor, which was originally incorporated in Delaware as a special purpose acquisition company (“IPV”)) on March 12, 2021, and issuances of stock. As of March 31, 2024, the Company’s existing sources of liquidity included cash and cash equivalents and marketable securities of $189.3 million. The Company has a limited history of operations and has incurred negative cash flows from operating activities and losses from operations in the past as reflected in the accumulated deficit of $494.9 million as of March 31, 2024. The Company expects to continue to incur operating losses due to the investments it intends to make in its business, including product development. Management believes that existing cash and cash equivalents and marketable securities will be sufficient to fund operating and capital expenditure requirements through at least 12 months from the date of issuance of these financial statements.

Significant Risks and Uncertainties

Significant Risks and Uncertainties

The Company is subject to those risks common in the technology industry and also those risks common to early stage companies including, but not limited to, the possibility of not being able to successfully develop or market its products, technological obsolescence, competition, dependence on key personnel and key external alliances, the successful protection of its proprietary technologies, compliance with government regulations, and the possibility of not being able to obtain additional financing when needed.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and trade receivables. The Company maintains the majority of its cash and cash equivalents in accounts with large financial institutions. At times, balances in these accounts may exceed federally insured limits; however, to date, the Company has not incurred any losses on its deposits of cash and cash equivalents and believes the exposure to risk of loss is not material. Risks associated with the Company’s marketable securities is mitigated by investing in investment-grade rated securities when purchased.

The Company’s accounts receivable are derived from customers located in the United States, APAC, and Europe. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers’ financial conditions and requires customer advance payments in certain circumstances.

As of March 31, 2024, three customers accounted for 44%, 15% and 12% of the accounts receivable, respectively. As of December 31, 2023, one customer accounted for 42% of accounts receivable. As of March 31, 2024, one vendor accounted for 10% of the accounts payable. As of December 31, 2023, three vendors accounted for 12%, 11% and 11% each of the accounts payable, respectively.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280):Improvements to Reportable Segment Disclosures" which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company does not expect ASU 2023-07 to have a material impact on the Company's financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential effect that the updated standard will have on our consolidated financial statements and related disclosures.

XML

Revenue (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Summary of Disaggregated Revenue by Geographic Region

Total revenue for the three months ended March 31, 2024 and 2023, based on the disaggregation criteria described above were as follows (in thousands):

	Three Months Ended March 31,
	2024					2023
	Revenue		% of Revenue			Revenue		% of Revenue
Revenue by primary geographical market:
North America	$	1,674		79	%	$	730		64	%
EMEA		229		11	%		244		21	%
Asia		204		10	%		174		15	%
Total	$	2,107		100	%	$	1,148		100	%
Revenue by timing of recognition:
Recognized at a point in time	$	1,714		81	%	$	947		82	%
Recognized over time		393		19	%		201		18	%
Total	$	2,107		100	%	$	1,148		100	%

XML

Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Summary of Financial assets and Liabilities Measured at Fair Value on Recurring Basis

The following tables summarize the Company’s financial assets and liabilities measured at fair value by level within the fair value hierarchy:

	March 31, 2024
	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalent		Marketable Securities
	(in thousands)
Assets
Cash	$	17,668	$	—	$	—		$	17,668	$	17,668	$	—
Level 1
Money market funds		264		—		—			264		264		—
Level 2
U.S. agency securities		27,635		2		(76	)		27,561		—		27,561
U.S. Treasury securities		30,255		—		(41	)		30,214		11,673		18,541
Commercial paper		42,591		6		(45	)		42,552		—		42,552
Corporate bonds		71,163		20		(114	)		71,069		—		71,069
Subtotal		171,644		28		(276	)		171,396		11,673		159,723
Total assets	$	189,576	$	28	$	(276	)	$	189,328	$	29,605	$	159,723
Liabilities
Level 3
Warrant liabilities		7,209		—		—			7,209		—		—
Total liabilities	$	7,209	$	—	$	—		$	7,209	$	—	$	—

	December 31, 2023
	Adjusted Cost		Unrealized Gain		Unrealized Losses			Fair Value		Cash and Cash Equivalent		Marketable Securities
	(in thousands)
Assets
Cash	$	21,799	$	—	$	—		$	21,799	$	21,799	$	—
Level 1
Money market funds		6,266		—		—			6,266		6,266		—
Level 2
U.S. Government securities		35,962		8		(97	)		35,873		—		35,873
U.S. Treasury securities		18,323		1		(14	)		18,310		10,482		7,828
Commercial paper		38,491		25		(16	)		38,500		—		38,500
Corporate bonds		100,274		136		(130	)		100,280		—		100,280
Subtotal		193,050		170		(257	)		192,963		10,482		182,481
Total assets	$	221,115	$	170	$	(257	)	$	221,028	$	38,547	$	182,481
Liabilities
Level 3
Warrant liabilities		6,772		—		—			6,772		—		—
Total liabilities	$	6,772	$	—	$	—		$	6,772	$	—	$	—

Summary of Changes in Fair Value of Level 3 Financial Instruments

The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments (in thousand):

	March 31, 2024			December 31, 2023
Fair value, beginning balance	$	6,772		$	90
Fair value at issuance of Series A warrants		—		$	6,450
Change in the fair value of Series A warrants included in other income (expense), net		450		$	300
Change in the fair value of private placement warrants included in other income (expense), net		(13	)		(68	)
Fair value, closing balance	$	7,209		$	6,772

Private Warrants

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Schedule of Black-Scholes Option Pricing Model

The key inputs into the Black-Scholes option pricing model for the private warrants were as follows for the relevant periods:

	March 31, 2024			December 31, 2023
Expected term (years)		2.0			2.2
Expected volatility		90.3	%		94.1	%
Risk-free interest rate		5.03	%		4.23	%
Dividend yield		0	%		0	%
Exercise Price	$	57.50		$	57.50

Series A Warrants

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Schedule of Black-Scholes Option Pricing Model

The key inputs into the Black-Scholes option pricing model for the Series A warrants were as follows for the relevant periods:

	March 31, 2024			December 31, 2023
Expected term (years)		3.7			4.0
Expected volatility		92.1	%		87.2	%
Risk-free interest rate		4.29	%		3.89	%
Dividend yield		0	%		0	%
Exercise Price	$	5.00		$	5.00

XML

Acquisition and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of expected amortization expense relating to purchased intangible assets

As of March 31, 2024, expected amortization expense relating to purchased intangible assets was as follows (in thousands):

Remainder of 2024	$	675
2025		900
2026		825
Total future amortization	$	2,400

XML

Inventories (Tables)

3 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consisted of the following (in thousands):

	March 31,		December 31,
	2024		2023
Raw materials	$	1,583	$	2,178
Work-in-progress		60		136
Finished goods		520		60
Total inventories	$	2,163	$	2,374

XML

Property, Plant and Equipment (Tables)

3 Months Ended

Mar. 31, 2024

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment consisted of the following (in thousands):

	March 31,			December 31,
	2024			2023
Computer equipment	$	2,944		$	2,795
Lab equipment		7,255			7,151
Leasehold improvements		3,312			3,148
Construction in progress		700			1,434
Testing equipment		1,752			1,455
Manufacturing equipment		5,743			4,269
Furniture, fixtures and other equipment		561			458
Total property, plant and equipment	$	22,268		$	20,710
Less: accumulated depreciation		(9,716	)		(8,596	)
Total property, plant and equipment, net	$	12,552		$	12,114

XML

Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2024

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Current Assets

Other current assets consisted of the following (in thousands):

	March 31,		December 31,
	2024		2023
Prepaid expenses	$	2,222	$	2,228
Contract assets		111		140
Vendor deposits		975		1,104
Other current assets		1,574		1,723
Total other current assets	$	4,882	$	5,195

XML

Other Non-Current Assets (Tables)

3 Months Ended

Mar. 31, 2024

Other Assets, Noncurrent [Abstract]

Schedule of Other Non-Current Assets

Other non-current assets consist of the following (in thousands):

	March 31,		December 31,
	2024		2023
Non marketable equity investments	$	5,000	$	5,000
Security deposit		1,062	$	1,116
Other non-current assets		—		16
Total other non-current assets	$	6,062	$	6,132

XML

Earnings (Loss) Per Share (Tables)

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except per share data):

	Three Months Ended March 31,
	2024			2023
Numerator:
Net loss attributable to common stockholders	$	(35,326	)	$	(35,174	)
Denominator:
Weighted average shares of common stock outstanding — Basic and Diluted		52,742,725			43,925,565
Net loss per share attributable to common stockholders — Basic and Diluted	$	(0.67	)	$	(0.80	)

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

The following table presents the potential common shares outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been anti-dilutive:

	Three Months Ended March 31,
	2024		2023
Common stock options issued and outstanding		2,386,503		2,634,606
Restricted stock units		5,484,398		4,348,913
Performance-based restricted stock units		1,911,765		—
Common stock warrants		2,491,775		2,491,775
Series A warrants		3,000,000		—
Total		15,274,441		9,475,294

XML

Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2024

Schedule of Stock Options Activity

A summary of the Company’s stock option activity, for three months ended March 31, 2024, was as follows:

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2023		2,414,730		$	2.79		5.73	$	4,004
Granted		—			—		—		—
Exercised		(28,227	)		1.37		—		—
Forfeited		—			—		—		—
Outstanding as of March 31, 2024		2,386,503		$	2.81		5.49	$	4,253
Vested and exercisable as of March 31, 2024		2,317,344		$	2.46		5.42	$	4,251
Vested and expected to vest as of March 31, 2024		2,386,503		$	2.81		5.49	$	4,253

There were no options granted during the three months ended March 31, 2024.

Schedule of Restricted Stock Activity

The following table summarizes our RSU activity for the three months ended March 31, 2024:

	Shares			Weighted Average Grant Date Fair Value per Share
Outstanding as of December 31, 2023		5,204,177		$	9.65
Granted		889,257			5.05
Released		(398,583	)		12.91
Forfeited		(210,453	)		8.83
Outstanding as of March 31, 2024		5,484,398		$	8.69

Schedule of Fair Value Weighted-Average Assumptions

The Company estimated the fair value of the market-based PBRSUs award on the grant date using the Monte Carlo simulation model with the following assumptions:

Expected term (years)	0.5 - 4.7
Expected volatility		70.9	%
Risk-free interest rate		3.29	%
Dividend yield		0	%
Share price	$	5.10

Summary of Stock-Based Compensation Expense

Total stock-based compensation expense by function was as follows (in thousands):

	Three Months Ended March 31,
	2024		2023
Cost of revenue	$	102	$	330
Research and development expenses		3,989		4,410
General and administrative expenses		907		1,119
Sales and marketing expenses		263		104
Total	$	5,261	$	5,963

XML

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Summary of Maturity Analysis of the Annual Undiscounted Cash Flows of Operating Lease Liabilities

The following is a maturity analysis of the annual undiscounted cash flows reconciled to the carrying value of the operating lease liabilities as of March 31, 2024 (in thousands):

	Operating Leases
Remainder of 2024	$	2,974
2025		3,157
2026		729
Total minimum lease payments		6,860
Less: imputed interest		(372	)
Total lease liability	$	6,488

XML

Segment Information (Tables)

3 Months Ended

Mar. 31, 2024

Geographic Areas, Long-Lived Assets [Abstract]

Schedule of Property, Plant and Equipment by Geographic Region

The following table sets forth the Company’s property, plant, and equipment, net by geographic region (in thousands):

	March 31,		December 31,
	2024		2023
North America	$	8,580	$	8,675
Asia		3,657		3,154
Others		315		285
Total	$	12,552	$	12,114

XML

Description of Business and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
	Mar. 18, 2024	Mar. 31, 2024	Dec. 31, 2023
Significant Accounting Policies [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Description of stock split	On March 18, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s shares of common stock, $0.0001 par value (the “Common Stock”). Pursuant to the Reverse Stock Split, every five (5) shares of issued and outstanding shares of common stock were combined into one (1) share of common stock.
Common Stock, Shares, Issued		52,816,000	52,389,000
Common Stock, Shares Authorized	0	422,000,000	422,000,000
Common Stock, Shares, Outstanding		52,816,000	52,389,000
Intangible assets		$ 2,400	$ 2,625
Cash and cash equivalents		29,605	38,547
Accumulated deficit		$ (494,926)	(459,600)
Number of months required to fund operating and capital expenditure		12 months
Accounts receivable		$ 978	628
Operating lease right-of-use assets		6,444	$ 7,289
Operating lease liabilities		6,488
Money Market Funds [Member]
Significant Accounting Policies [Line Items]
Cash and cash equivalents		189,300
Accumulated deficit		$ 494,900
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage		15.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Significant Accounting Policies [Line Items]
Number of customer accounted for accounts receivable			one customer
Concentration risk, percentage		44.00%	42.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Customers Three [Member]
Significant Accounting Policies [Line Items]
Number of customer accounted for accounts receivable		three customers
Concentration risk, percentage		12.00%
Credit Concentration Risk [Member] | Accounts Payable [Member] | Two Vendors [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			11.00%
Credit Concentration Risk [Member] | Accounts Payable [Member] | Three Vendor [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			11.00%
Number of vendors accounted for accounts payable			three vendors
Credit Concentration Risk [Member] | Accounts Payable [Member] | One Vendor [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage		10.00%	12.00%
Number of vendors accounted for accounts payable		one vendor

XML

Revenue - Summary of Disaggregated Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation Of Revenue [Line Items]
Revenue	$ 2,107	$ 1,148
% of Revenue	100.00%	100.00%
Recognized at a point in time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 1,714	$ 947
% of Revenue	81.00%	82.00%
Recognized over time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 393	$ 201
% of Revenue	19.00%	18.00%
North America [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 1,674	$ 730
% of Revenue	79.00%	64.00%
Europe [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 229	$ 244
% of Revenue	11.00%	21.00%
Asia
Disaggregation Of Revenue [Line Items]
Revenue	$ 204	$ 174
% of Revenue	10.00%	15.00%

XML

Revenue - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) Customer	Mar. 31, 2023 Customer	Dec. 31, 2023 USD ($)
Disaggregation of Revenue [Line Items]
Contract assets	$ 111		$ 140
Customer Concentration Risk [Member] | Revenue [Member]
Disaggregation of Revenue [Line Items]
Number Of customers meeting concentration risk threshold | Customer	2	3
Customer Concentration Risk [Member] | Revenue [Member] | Customer One [Member]
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	39.00%	20.00%
Customer Concentration Risk [Member] | Revenue [Member] | Customer Two [Member]
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	36.00%	19.00%
Customer Concentration Risk [Member] | Revenue [Member] | Customer Three [Member]
Disaggregation of Revenue [Line Items]
Concentration risk, percentage		17.00%
Other current assets [Member]
Disaggregation of Revenue [Line Items]
Contract assets	$ 100		100
Other current liabilities [Member]
Disaggregation of Revenue [Line Items]
Contract liabilities	$ 3,600		$ 2,100

XML

Financial Instruments - Summary of Financial assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Available-for-sale [Abstract]
Cash	$ 17,668	$ 21,799
Adjusted Cost	189,576	221,115
Unrealized Gains	28	170
Unrealized Losses	(276)	(257)
Fair Value	189,328	221,028
Cash and cash equivalents	29,605	38,547
Marketable Securities	159,723	182,481
Warrant liabilities	7,209	6,772
Financial liabilities, Fair value	7,209	6,772
Fair Value, Inputs, Level 2 [Member]
Available-for-sale [Abstract]
Adjusted Cost	171,644	193,050
Unrealized Gains	28	170
Unrealized Losses	(276)	(257)
Fair Value	171,396	192,963
Cash and cash equivalents	11,673	10,482
Marketable Securities	159,723	182,481
Fair Value, Inputs, Level 3 [Member] | Warrant Liabilities [Member]
Available-for-sale [Abstract]
Warrant liabilities	7,209	6,772
Financial liabilities, Fair value	7,209	6,772
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale [Abstract]
Adjusted Cost	264	6,266
Fair Value	264	6,266
Cash and cash equivalents	264	6,266
U.S. agency securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale [Abstract]
Adjusted Cost	27,635	35,962
Unrealized Gains	2	8
Unrealized Losses	(76)	(97)
Fair Value	27,561	35,873
Marketable Securities	27,561	35,873
U.S. Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale [Abstract]
Adjusted Cost	30,255	18,323
Unrealized Gains	0	1
Unrealized Losses	(41)	(14)
Fair Value	30,214	18,310
Cash and cash equivalents	11,673	10,482
Marketable Securities	18,541	7,828
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale [Abstract]
Adjusted Cost	42,591	38,491
Unrealized Gains	6	25
Unrealized Losses	(45)	(16)
Fair Value	42,552	38,500
Cash and cash equivalents	0	0
Marketable Securities	42,552	38,500
Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale [Abstract]
Adjusted Cost	71,163	100,274
Unrealized Gains	20	136
Unrealized Losses	(114)	(130)
Fair Value	71,069	100,280
Marketable Securities	$ 71,069	$ 100,280

XML

Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value, Beginning Balance	$ 6,772	$ 90
Fair value at issuance of Series A warrants	0	6,450
Change in the fair value included in other income (expense), net	(13)	(68)
Fair Value, Ending Balance	7,209	6,772
Warrant and Series A [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Change in the fair value included in other income (expense), net	$ 450	$ 300

XML

Financial Instruments - Schedule of Black-Scholes Option Pricing Model For Private Warrants (Details) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (years)	2 years	2 years 2 months 12 days
Expected volatility	90.30%	94.10%
Risk-free interest rate	5.03%	4.23%
Dividend yield	0.00%	0.00%
Exercise Price	$ 57.5	$ 57.5
Series A Preferred Stock [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (years)	3 years 8 months 12 days	4 years
Expected volatility	92.10%	87.20%
Risk-free interest rate	4.29%	3.89%
Dividend yield	0.00%	0.00%
Exercise Price	$ 5	$ 5

XML

Acquisition and Intangible Assets (Additional Information) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 0.2	$ 0.2

XML

Acquisition and Intangible Assets - Schedule of expected amortization expense relating to purchased intangible assets (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2024	$ 675
2025	900
2026	825
Total future amortization	$ 2,400

XML

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 1,583	$ 2,178
Work-in-progress	60	136
Finished goods	520	60
Total inventory	$ 2,163	$ 2,374

XML

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 22,268	$ 20,710
Less: accumulated depreciation	(9,716)	(8,596)
Total property, plant and equipment, net	12,552	12,114
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	2,944	2,795
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	7,255	7,151
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	3,312	3,148
Construction In Progress [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	700	1,434
Testing Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	1,752	1,455
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	5,743	4,269
Furniture, Fixtures and Other Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 561	$ 458

XML

Property, Plant and Equipment - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 1.1	$ 0.7

XML

Other Current Assets - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 2,222	$ 2,228
Contract assets	111	140
Vendor deposits	975	1,104
Other current assets	1,574	1,723
Total other current assets	$ 4,882	$ 5,195

XML

Other Non-Current Assets - Schedule of Other Non-Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Other Assets, Noncurrent [Abstract]
Non marketable equity investments	$ 5,000	$ 5,000
Security deposit	1,062	1,116
Other non-current assets	0	16
Total other non-current assets	$ 6,062	$ 6,132

XML

Other Non-Current Assets (Additional Information) (Details) - Preferred Stock [Member] $ in Millions	Nov. 30, 2023 USD ($) shares
Other Non-Current Assets [Line Items]
Prefered stock purchased, shares | shares	700,440
Cash consideration | $	$ 5.0
Investment, percentage of captalization	1.00%

XML

Other Current Liabilities - Schedule of Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Other Liabilities, Current [Abstract]
Total other current liabilities	$ 4,406	$ 2,524

XML

Financing Transaction (Additional Information) (Details)		3 Months Ended
	Nov. 08, 2023 USD ($) Segment $ / shares shares	Mar. 31, 2024 USD ($) Warrants $ / shares	Mar. 18, 2024 $ / shares	Dec. 31, 2023 $ / shares shares
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value | $ / shares		$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, par value | $ / shares		$ 0.0001		$ 0.0001
Advance condition	The Company’s right to request Advances is conditioned upon the Company achieving a minimum of one new passenger auto-original equipment manufacturer (“OEM”) or commercial OEM program award with at least a 50,000 unit volume
Program award 1 | Segment	50,000
Trading price of the common stock	$ 15
Subscription Agreements
Subsidiary or Equity Method Investee [Line Items]
Aggregate shares available for purchase | shares	7,360,460
Common stock, par value | $ / shares	$ 0.0001
Share price | $ / shares	$ 2.9
Proceeds from issuance of common stock	$ 21,400,000
Standby Equity Purchase Agreement
Subsidiary or Equity Method Investee [Line Items]
Percentage of dividend payble	7.00%
Preferred stock liquidation preference per share | $ / shares	$ 12,000
Convertible preferred stock nonredeemable or redeemable issuer option value	$ 10,000
Common stock applicable conversion price		250.00%
Facility fee		$ 2,500,000
Origination fee		600,000
Administrative fees expense		300,000
Fees and expenses of the investor and its counsel		$ 400,000
Standby Equity Purchase Agreement | Series A One
Subsidiary or Equity Method Investee [Line Items]
Warrants issued | shares				3,000,000
Maximum [Member]
Subsidiary or Equity Method Investee [Line Items]
Debt instrument convertible threshold trading days | Segment	30
Maximum [Member] | Standby Equity Purchase Agreement
Subsidiary or Equity Method Investee [Line Items]
Debt instrument convertible threshold trading days | Segment	30
Minimum [Member]
Subsidiary or Equity Method Investee [Line Items]
Debt instrument convertible threshold trading days | Segment	20
Minimum [Member] | Standby Equity Purchase Agreement
Subsidiary or Equity Method Investee [Line Items]
Debt instrument convertible threshold trading days | Segment	20
Preferred Stock [Member] | Standby Equity Purchase Agreement
Subsidiary or Equity Method Investee [Line Items]
Share price | $ / shares	$ 10,000
Total preferred facility	$ 125,000,000
Preferred Stock [Member] | Maximum [Member] | Standby Equity Purchase Agreement
Subsidiary or Equity Method Investee [Line Items]
Number of shares preferred stock aggregate value	50,000,000
Preferred Stock [Member] | Minimum [Member] | Standby Equity Purchase Agreement
Subsidiary or Equity Method Investee [Line Items]
Number of shares preferred stock aggregate value	$ 25,000,000
Common Stock [Member] | Standby Equity Purchase Agreement
Subsidiary or Equity Method Investee [Line Items]
Percentage of common stock beneficially owned by investor	19.90%
Common Stock [Member] | Standby Equity Purchase Agreement | Series A One
Subsidiary or Equity Method Investee [Line Items]
Warrants issued to purchase shares of common stock, Exercise price | $ / shares				$ 5
Number of warrants outstanding | Warrants		3,000,000
Sale of stock Per share | $ / shares		$ 5
Percentage of common stock outstanding		19.90%

XML

Capital Structure - Additional Information (Details) - $ / shares	Mar. 31, 2024	Mar. 18, 2024	Dec. 31, 2023
Class Of Stock [Line Items]
Common stock, shares authorized	422,000,000	0	422,000,000
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, shares authorized	10,000,000		10,000,000
Preferred stock, shares issued	0		0
Pre-combination Aeva preferred stock outstanding	0		0
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001	$ 0.0001
Public Warrants [Member]
Class Of Stock [Line Items]
Class of Warrant or Right, Outstanding	2,414,975
Private Warrants [Member]
Class Of Stock [Line Items]
Common Stock, Par or Stated Value Per Share	$ 57.5
Class of Warrant or Right, Outstanding	76,800
A Series warrants [Member]
Class Of Stock [Line Items]
Common Stock, Par or Stated Value Per Share	$ 5
Class of Warrant or Right, Outstanding	3,000,000

XML

Earnings (Loss) Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator:
Net loss attributable to common stockholders	$ (35,326)	$ (35,174)
Denominator:
Weighted average shares of common stock outstanding - Basic	52,742,725	43,925,565
Weighted average shares of common stock outstanding - Diluted	52,742,725	43,925,565
Net loss per share attributable to common stockholders, Basic	$ (0.67)	$ (0.8)
Net loss per share attributable to common stockholders, Diluted	$ (0.67)	$ (0.8)

XML

Earnings (Loss) Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	15,274,441	9,475,294
Common stock options issued and outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,386,503	2,634,606
Restricted stock units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	5,484,398	4,348,913
Restricted Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,911,765	0
Common stock warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,491,775	2,491,775
Series A warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	3,000,000	0

XML

Stock-based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		12 Months Ended
	May 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		4 years
Antidilutive securities excluded from computation of earnings per share, amount		15,274,441	9,475,294
First 12 Months [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of stock options vesting		25.00%
Remaining 36 Months [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of stock options vesting		75.00%
2016 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common Stock, Authorized		3,677,480
Common stock options issued and outstanding
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense		$ 0.5
Unrecognized stock-based compensation expense, weighted average recognition period		1 year 7 months 24 days
Antidilutive securities excluded from computation of earnings per share, amount		2,386,503	2,634,606
Number of Options, Granted		0
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		1,911,765	0
Restricted stock units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense		$ 39.6
Restricted stock units, vesting period		2 years 10 months 24 days
Performance-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense		$ 1.3
Unrecognized stock-based compensation expense, weighted average recognition period		1 year 9 months 18 days
Weighted-average grant date fair value		$ 5.1
Antidilutive securities excluded from computation of earnings per share, amount				1,911,765
Number of Options, Granted	1,176,471
Market-based PBRSU [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense, weighted average recognition period		3 years
Unrecognized stock-based compensation expense related to the restricted stock		$ 0.7
Weighted-average grant date fair value		$ 1.4
Number of Options, Granted		735,294

XML

Stock-based Compensation - Schedule of Stock Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Number of Options, Outstanding, Beginning as of December 31, 2023	2,414,730
Number of Options, Exercised	(28,227)
Number of Options, Forfeited	0
Number of Options, Outstanding, Ending At March 31, 2024	2,386,503	2,414,730
Number of Options, Vested and exercisable as of March 31, 2024	2,317,344
Number of Options, Vested and expected to vest as of March 31, 2024	2,386,503
Weighted- Average Exercise Price, Outstanding, Beginning as of December 31, 2023	$ 2.79
Weighted- Average Exercise Price, Exercised	1.37
Weighted- Average Exercise Price, Forfeited	0
Weighted- Average Exercise Price, Outstanding, Ending as of March 31, 2024	2.81	$ 2.79
Weighted- Average Exercise Price, Vested and exercisable as of March 31, 2024	2.46
Weighted- Average Exercise Price, Vested and expected to vest as of March 31, 2024	$ 2.81
Weighted-Average Remaining Contractual Life (Years), Outstanding	5 years 5 months 26 days	5 years 8 months 23 days
Weighted-Average Remaining Contractual Life (Years), Vested and exercisable as of March 31, 2024	5 years 5 months 1 day
Weighted-Average Remaining Contractual Life (Years), Vested and expected to vestas of March 31, 2024	5 years 5 months 26 days
Aggregate Intrinsic Value, Outstanding	$ 4,253	$ 4,004
Aggregate Intrinsic Value, Vested and exercisable as of March 31, 2024	4,251
Aggregate Intrinsic Value, Vested and expected to vest as of March 31, 2024	$ 4,253

XML

Stock-based Compensation - Schedule of Fair Value Weighted-Average Assumptions (Details) - Market-based PBRSU [Member]	3 Months Ended
	Mar. 31, 2024 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility	70.90%
Risk-free interest rate	3.29%
Dividend yield	0.00%
Share price	$ 5.1
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	6 months
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	4 years 8 months 12 days

XML

Stock-based Compensation - Schedule of Restricted Stock Activity (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Outstanding, Beginning as of December 31, 2023	2,414,730
Number of Options, Outstanding, Ending At March 31, 2024	2,386,503
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Outstanding, Beginning as of December 31, 2023	5,204,177
Shares, Granted	889,257
Shares, Released	(398,583)
Shares, Forfeited	(210,453)
Number of Options, Outstanding, Ending At March 31, 2024	5,484,398
Weighted Average Graint Date Fair Value per Share, Outstanding, Beginningas of December 31, 2023 | $ / shares	$ 9.65
Weighted Average Graint Date Fair Value per Share, Granted | $ / shares	5.05
Weighted Average Grant Date Fair Value per Share, Released | $ / shares	12.91
Weighted Average Graint Date Fair Value per Share, Forfeited | $ / shares	8.83
Weighted Average Graint Date Fair Value per Share, Outstanding, Ending as of March 31, 2024 | $ / shares	$ 8.69

XML

Stock-based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 5,261	$ 5,963
Cost of Revenue [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	102	330
Research and Development Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	3,989	4,410
General and Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	907	1,119
Sales and Marketing Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 263	$ 104

XML

Income Taxes - Schedule of Income before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (35,326)	$ (35,174)

XML

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Federal provision for income taxes		$ 0
State provision for income taxes		0
Provision for income taxes	$ 0	$ 0

XML

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Loss Contingencies [Line Items]
Weighted average discount rate	6.32%		6.04%
Operating lease cost	$ 1.0	$ 0.8
Weighted-average remaining lease term	1 year 10 months 24 days		2 years

XML

Commitments and Contingencies - Summary of Maturity Analysis of the Annual Undiscounted Cash Flows of Operating Lease Liabilities (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2024	$ 2,974
2025	3,157
2026	729
Total minimum lease payments	6,860
Less: imputed interest	(372)
Total lease liability	$ 6,488

XML

Segment Information - Additional Information (Details)	3 Months Ended
	Mar. 31, 2024 Segment
Entity Wide Revenue Major Customer [Line Items]
Number of Operating Segments	1

XML

Segment Information - Schedule of Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 12,552	$ 12,114
North America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	8,580	8,675
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	3,657	3,154
Others
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 315	$ 285